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Epigenetics in atherosclerosis and inflammation 
Rutger J. Wierda, Sacha B. Geutskens,J. Wouter Jukema, 
Paul H.A. Quax & P.J. van den Elsen 





Cardiovascular diseases (CVD) are the number one cause of death in the west-
ern society.1,2 Atherosclerosis is the primary cause of coronary artery disease (CAD) 
and stroke and is regarded as a (chronic) inflammatory disease.3,4 Atherosclerosis 
is characterized by asymmetrical focal thickenings of the arterial intima that are 
often referred to as atherosclerotic lesions or atheromas.5 These thickenings are 
caused by the accumulation of lipids and inflammatory cells in the vessel wall.5 
Especially T cells and macrophages play an important role in pathogenesis of ath-
erosclerosis.6 Besides lipids and inflammatory cells, the lesion – depending on the 
stage of the disease – further consists of vascular endothelial cells (vECs) and 
vascular smooth muscle cells (vSMCs), and extracellular matrix (ECM).7 Extreme 
thickening of the intima or even plaque rupture with subsequent thrombus forma-
tion may seriously hamper coronary blood flow, eventually leading to myocardial 
infarction.8 Thus, atherosclerosis is a potential life-threatening condition and un-
derstanding the cause of atherosclerosis may contribute to the treatment and 
possibly prevention of this disease.
Atherosclerotic plaque formation is a dynamic multi-cellular process in which 
the activity of the different cell types involved is essentially determined by the 
regulation of different genes.3–8 Understanding these processes is critical for our 
understanding of inflammatory responses and disease. Nowadays we are fully 
aware of the important involvement of epigenetic processes in the regulation of 
gene expression. For instance, not only is cytokine expression under epigenetic 
control, cytokines themselves induce (indirect) changes to the chromatin, providing 
an essential link between inflammation and epigenetic programming.9 To under-
stand the involvement of epigenetic process in atherosclerosis it is important to 
have a clear understanding of the disease process as well as an understanding 
of epigenetic phenomena. A brief introduction of both atherosclerosis as well as 
epigenetic gene regulation is provided below, before the potential involvement of 
epigenetic regulation in atherosclerosis is discussed.
Atherosclerosis
The first step in atherosclerosis is thought to be endothelial dysfunction,10 possi-
bly triggered by oxidized low-density lipoprotein (OxLDL).5 Activation of the arterial 
endothelium results in the expression of cytokines and chemokines, enhance-
ment in the permeability of the endothelial cell layer and an increased expression 
of adhesion molecules. Immune and inflammatory cells such as monocytes and 
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T lymphocytes are then attracted by chemokines (a process know as chemotaxis), 
followed by firm adhesion and transendothelial migration. These cells subsequent-
ly infiltrate the subendothelium of the vascular wall and form the main players 
in the formation of the ‘fatty streak’: the first identifiable lesion.10 The process of 
plaque formation is shown schematically in figure 1–1.
Foam cells – cholesterol-engorged monocyte-derived macrophages – are 
the dominant type of immune cells found within the lesions. Macrophages take 
up the OxLDL present in the subendothelium, but are unable to digest it suffi-
ciently, resulting in the formation of foam cells.5 Although fatty streaks are not 
clinically significant, they are thought to be the precursors to more advanced le-
sions, although there is some dispute whether fatty streaks are truly precursors 
of advanced lesions.7,12 If the causative agents for this endothelial dysfunction are 































Figure 1–1.  Schematic representation of plaque development. Oxidized low-density lipoprotein 
(OxLDL) is thought to trigger endothelial dysfunction. OxLDL is often associated 
with proteoglycans in the subendothelium. Activated endothelial cells start to 
express various adhesion molecules. Immune cells, mainly monocytes and T  cells, 
are attracted by chemokines and migrate across the endothelium, using adhesion 
molecules. Monocytes then differentiate into macrophages (Mφ) and dendritic cells. 
These macrophages take up OxLDL and transform into ‘foam cells’. This process of 
foam cell formation is indicated with the large grey arrow. T  cells recruited to the 
plaque express several cytokines and chemokines. In response to the stimuli, vSMCs 
start to proliferate and migrate, and start to produce ECM. Abbreviations: ECM: extra 
cellular matrix; EEL: external elastic lamina; IEL: internal elastic lamina; LDL: low-
density lipoprotein; Mφ: macrophages; OxLDL: oxidized low-density lipoprotein. 
Illustration inspired on Sherer et al.11
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atherosclerosis-associated immune response is driven by monocyte-derived mac-
rophages and specific subsets of T cells.6,13 Monocytes and T lymphocytes migrate 
from the blood and proliferate within the lesion, resulting in the accumulation 
of inflammatory cells. If these cells become activated, they release cytokines, 
chemokines and growth factors,10 contributing to the on-going inflammatory pro-
cess. Moreover, immune activation eventually induces focal necrosis leading to the 
necrotic core found in advanced lesions.
In later stages of the disease other cell types (e.g. vSMCs) become involved. 
Vascular SMCs start to proliferate as a response to the various signalling mol-
ecules present in the lesion, thereby thickening the arterial wall. Eventually the 
lesion will evolve into a ‘fibrolipid plaque’, consisting of a lipid-rich necrotic core 
covered by a fibrous cap of vSMCs and a collagen-rich matrix.3,14 The resulting 
thickening of the arterial wall caused by the plaque formation will partially be 
compensated by gradual dilation (remodelling). If the plaque volume becomes too 
large, this process cannot compensate enough, leading to decreased lumen size 
and hampered blood-flow.15
As stated above, the development of the atherosclerotic lesion is for the larger part 
determined by the release of various cytokines and chemokines. Pro-inflammatory 
cytokines such as tumour necrosis factor α (TNF‑α) and interferon γ (IFNγ) released 
by activated T cells – recruited to the vascular cell wall – play an essential role in 
disease development. This critical role for pro-inflammatory cytokines in athero-
sclerosis development is illustrated in atherosclerotic mouse models. It has been 
shown that deletion of the genes coding for pro-inflammatory cytokines (e.g. IL-12, 
IFNγ, IFNγ receptor and TNF-α) resulted in reduced atherosclerosis development 
in these knockout mice.16–18 Conversely, deletion of anti-inflammatory cytokine 
genes (e.g. IL-10 and TGF-β) resulted in increased atherosclerosis.19,20 Different ge-
netic variants of the TNF‑α gene also showed to be important for the outcome of 
percutaneous coronary intervention (PCI, one of the treatments used for opening 
of occluded vessels) with respect to restenosis – one of the major limitations of the 
PCI technique.21 Genetic variants of the IL‑10 gene have also proven to be important 
for the development of restenosis.22
The cross-talk between immune system and vascular wall results in upregula-
tion of major histocompatibility complex (MHC) class II (MHC-II) molecules and of 
the MHC class Ib molecule, HLA-E.3,23 Furthermore, it results in up regulation of 
chemokines such as CX3CL1 (fractalkine), CCL2 (MCP-1), CCL5 (RANTES) and their 
receptors.3,24–27 All of these factors influence the gene expression profiles of cells 
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present within the lesion. These observations not only feed the current theory that 
atherosclerosis is an inflammatory disease – and not just a disease of lipid meta-
bolism. For many of these inflammatory and immune modulating factors epigenetic 
components have been identified that are responsible for the transcriptional regu-
lation of the genes encoding these factors. Thus epigenetic processes might prove 
to be important contributing factors to disease pathogenesis that should be taken 
into consideration.
Epigenetics explained
Although all cells in our body contain the same genetic material, each cell 
acts in a cell-type specific manner, as determined by its gene expression profile. 
Epigenetic mechanisms control gene expression without modifying the actual 
genetic code, whilst the altered gene expression patterns can be passed to the 
daughter cells upon cell division or even transgenerationally.28–30
In its natural state DNA is packaged into chromatin, a highly organized and 
dynamic protein-DNA complex which consists of DNA, histones and non-histone 
proteins.31 Epigenetic mechanisms alter the accessibility of chromatin by modi-
fying DNA and by modification or rearrangement of nucleosomes, which include 
post-translational modifications of histones.32–34 Accessible chromatin allows 
gene-regulatory proteins (transcription factors) to interact with their cognate 
binding sites within the regulatory regions of genes, such as proximal promoters 
and enhancer/silencers. In this way, global gene activation and local control of 
gene-specific transcription is exerted by components of the epigenetic machinery. 
Moreover, environmental factors have an important role in the establishment of the 
epigenome.35–38 Since epigenetic alterations can accumulate in time, environmental 
factors can have profound effects on the cellular repertoire of expressed genes.28
Already in 1975 DNA methylation was proposed to play a role in regulating gene 
transcription.39,40 Generally speaking, DNA methylation is associated with low gene 
activity. Actively transcribed genes are usually maintained in an unmethylated 
state in their promoter regions.41–43 DNA methylation involves methylation at the 
C5 position of cytosine residues in a CpG dinucleotide (i.e. cytosine followed by a 
guanine) context, exerted by DNA methyltransferases (DNMTs). DNMTs are capa-
ble of both methylation and demethylation – as has been postulated in two recent 
reports – thus making the modification reversible.44,45 Notably, CpG dinucleotides 
are underrepresented in the genome of eukaryotes, but can be found in clusters – 
so-called ‘CpG islands’ – which in turn are mainly found in promoter regions. The 
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term ‘CpG island’ is defined as a region of at least 500 base pairs with a CG-content 
greater than 55%.46
For many years it was thought that functionally relevant DNA methylation oc-
curs at the CpG islands within the promoter region. However, in a recent study by 
Irizarry et al. it was shown that most tissue-specific DNA methylation occurs in 
regions up to 2kb distant of the promoter region,47 which were dubbed ‘CpG island 
shores’ by the authors. Furthermore they showed that cancer-specific methylation 
also occurs at conserved tissue-specific CpG island shores.
Besides methylation of DNA, post-translational modifications of N-terminal 
tails of histone proteins are key-components in the epigenetic regulation of genes. 
Over 60 distinct modifications are currently known – mostly in the histone tails – 
although some have been observed in the globular domain.48,49 Modifications of 
histone tails include (amongst others) acetylation and methylation of lysine resi-
dues. Whereas acetylation of histone tails is correlated with gene activation,50–52 
the influence of histone methylation depends on the exact residue methylated and 
the number of added methyl groups.53–55 Histone modifications and DNA methyla-
tion provide a close interplay with respect to gene regulation as both activities are 
functionally linked.56
Whereas lysine methylation and acetylation are the most studied modifica-
tions, there are many more histone modifications known. Arginine residues can 
also be methylated and acetylated, just as lysine residues. As is the case with ly-
sine methylation, whether arginine methylation results in repression or activation 
of transcription depends on which arginine residue is methylated.57 In addition, 
SUMOylation and ubiquitination of histones has also been observed.49 SUMOylation 
appears to be associated with transcriptional repression,58 whereas ubiquitination 
has been suggested to play a role in transcriptional activation and elongation.59 
However, the exact function of these modifications remains to be elucidated.
Epigenetic alterations are reversible
Interestingly, epigenetic modifications are reversible, which is illustrated by the 
counterbalancing actions of the various enzymes that are responsible for maintain-
ing the epigenome. Lysine acetyltransferases (KATs, formerly known as histone 
acetyltransferases or HATs) are counteracted by histone deacetylases (HDACs) 
and Sirtuins (SIRT) in establishing histone acetylation modifications at lysine res-
idues in the N-terminal tails. Lysine methyltransferases (KMTs, formerly known 
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as histone methyltransferases or HMTs), finally, are counteracted by the recently 
discovered lysine demethylases (KDMs, formerly known as histone demethylases 
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Figure 1–2.  Schematic representation of chromatin. DNA is wrapped around the octamer core 
of histones to form a structure called the nucleosome. Transcriptionally active 
chromatin (euchromatin) is hallmarked by low frequency of DNA methylation. High 
levels of histone acetylation and histone methylation correlated with activation 
(MeK4H3, MeK36H3, MeK79H3) are detected in euchromatin. KATs are responsible 
for acetylation of histone tails, whereas KDMs remove methylation marks histones. 
DNMTs probably remove methylation marks from DNA, although this has not yet 
been proven definitively (A). Transcriptionally silent chromatin (heterochromatin) 
is hallmarked by high frequencies of repressive methylation markers (i.e. DNA 
methylation and MeK9H3, MeK27H3 and MeK20H4). Methylation of histone tails 
is catalysed by KMTs whereas DNA methylation is catalysed by DNMT. Acetylation 
markers, associated with activation, are removed by HDACs (B). Post-translational 
modifications of histone tails include (but are not limited to) acetylation (Ac) and 
methylation (Me), which can be associated with transcriptionally active (green) or 
silent (red) chromatin (C).
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these enzymes promote a return to respectively repressive or active chromatin 
structure.60–62
Importantly, the reversible nature of these epigenetic modifications makes the 
chromatin-modifying enzymes interesting therapeutic targets63–65 and a myriad of 
small molecule inhibitors (SMI) that can influence the enzymatic activity of these 
chromatin-modifying enzymes are currently being tested for their efficacy (see Mai 
et al.66 and references therein). These inhibitors are mostly evaluated in the field 
of cancer research, in cell lines, in animal models as well as in clinical trials.66 
Notably suberoylanilide hydroxamic acid (SAHA) and valproic acid (VPA) (HDAC 
inhibitors (HDACi)) are already FDA approved for cancer treatment and epilepsy 
respectively.67–69 With respect to atherosclerosis, administration of curcumin (a KAT 
inhibitor) resulted in significantly lowered low-density lipoprotein (LDL) levels and 
raised high-density lipoprotein (HDL) levels in healthy volunteers.70–72 It has also 
been reported that curcumin has an anti-proliferative effect on peripheral blood 
mononuclear cells (PBMCs) and vSMCs.73
Epigenetics and association with atherosclerosis
Epigenetics provides an attractive explanation on how diet, environment and 
lifestyle may contribute to disease. In principle, epigenetics explains how such 
external factors can impose aberrant gene expression patterns in an individual 
lifetime and even trans-generationally. One of the earliest studies linking DNA 
methylation to atherosclerosis showed that the extracellular superoxide dismu-
tase (ec-SOD) gene was hypomethylated in atherosclerotic lesions in rabbits.74 
The importance of DNA methylation as a contributing factor to the pathogenesis 
of atherosclerosis is underscored by a study linking global DNA hypermethylation 
with predisposition to, and natural history of atherosclerosis.75 In this study the 
correlation was found by comparing methylation sensitive restriction of peripher-
al blood leukocyte DNA. However, this approach evaluates only the inflammatory 
component of the disease process in PBMCs and not other components such as 
vECs and vSMCs. In particular, DNA hypermethylation was found to be significantly 
associated with both all-cause and cardiovascular mortality, even following the 
adjustment for age, CVD and diabetes mellitus. Hypermethylation was found in pa-
tients suffering from inflammation (high C-reactive protein (CRP) levels) and also 
in 13 patients who died from CVD. This paper suggests that global DNA hypermeth-
ylation is associated with inflammation and increased mortality in chronic kidney 
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disease. Importantly, hypermethylation was found to be the strongest independent 
risk factor for CVD mortality.
In the case of coronary artery disease (CAD) an epigenetic component associ-
ated with disease was also identified.76 Sharma et al., found that angiographically 
confirmed CAD patients showed a higher level of genomic DNA methylation – de-
termined in peripheral blood lymphocytes – when compared to healthy controls.76 
Furthermore, a positive correlation was found between global DNA methylation 
and homocysteine levels. Homocysteine is known to be an independent risk factor 
for CAD.77,78 Sharma and co-workers also tested the specific methylation status of 
the ApoE gene by bisulphite-sequencing. The ApoE promoter was previously shown 
to have a degree of methylation that varies with homocysteine levels.79 However, 
no significant difference could be detected between patients and controls.76 Both 
these studies underline the potential effect DNA methylation can have with respect 
to disease development and outcome. However, the precise genes targeted by DNA 
methylation and thus the precise mechanisms that induce DNMT activity remain to 
be elucidated.
Although DNA methylation is one of the most studied epigenetic phenome-
na, more and more research is performed on the specific contribution of histone 
modifications. Recently, a study was published directly linking epigenetic histone 
modifications and atherosclerosis. Hastings et al. showed that atherosclero-
sis-prone shear stress profiles globally decreased histone H4 acetylation and 
increased H4 acetylation at the c-fos promoter in smooth muscle cells (SMCs).80 
Perhaps more importantly, they showed that atheroprone hemodynamics resulted 
in differentially regulated phenotypes for endothelial cells (ECs) and SMCs. Shear 
stress (flow) was applied to ECs that were layered on top of SMCs in forces that 
correlate to atheroprone or atheroprotective-conditions. Atheroprone flow re-
duced the expression of eNOS, TIE2 and Krüppellike factor in ECs, and smooth 
muscle actin and myocardin in SMCs, whereas VCAM-1, IL-8 and MCP-1 were in-
creased in both cell types. This correlated to a decrease in total H4 acetylation and 
serum response factor binding to the smooth muscle cell actin CArG promoter. 
Furthermore atheroprotective conditions induced a polygonal shape in EC whereas 
atheroprone conditions induced an elongated EC phenotype. In vSMCs atheropro-
tective conditions induced an elongated shape whereas atheroprone conditions 
showed a random SMC organization and cells aligned toward a perpendicular ori-
entation relative to the direction of flow.80
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Another linkage between atherosclerosis and histone modifications was found 
when the administration of the HDACi trichostatin A (TSA) in LDR-/- mice led to 
exacerbated neointimal lesions.81 TSA increased CD36 mRNA, protein and cell sur-
face expression levels, which were related to increased acetylated histone binding 
at the promoter region. CD36 recognizes OxLDL, thus the obtained results might be 
due to increased OxLDL uptake by macrophages. Also levels of TNF-α and VCAM-1 
were increased in aortic plaques. It has also been noted that application of TSA 
resulted in inhibition of SMC migration.82 Unfortunately, the exact mechanisms are 
not yet fully understood, but these studies clearly indicate a role for histone acetyl-
ation in disease pathogenesis.
Interestingly, some components relevant for the development of atherosclero-
sis, such as OxLDL, are able to modulate the activity of lysine deacetylases.83 In 
cultured ECs it was shown that OxLDL reduced expression of HDAC1 and HDAC2. 
Global HDAC activities were partly restored by statins: pre-treatment of ECs for 24h 
with simvastatin or fluvastatin blocked the OxLDL-related modifications in H3 and 
H4. Addition of mevalonate could revert the effects observed after statin treatment. 
The researchers postulate that this, at least in part, may be due to inhibition of 
small GTP-binding Rho proteins. Furthermore, decreased expression of HDAC2 in 
ECs was shown in atherosclerotic plaques of human coronary arteries.83 Taken to-
gether, these data show the importance of histone modifications in atherosclerosis.
A study performed by Barker et al. in 1989 sheds light on how long-term cellular 
memory can have an effect on the development of atherosclerosis. Nowadays it 
is generally accepted that long-term cellular memory is mediated via epigenetic 
phenomena. Barker et al. demonstrated that low birth weight is associated with 
a higher risk of cardiovascular events in adult live.84 This led to the hypothesis 
that the environment the foetus is exposed to during pregnancy might partially de-
termine cardiovascular risk. This so-called ‘foetal origins hypothesis’ states that 
adaptation to an unfavourable maternal environment is beneficial to the developing 
embryo in utero.84 However, when the adult environment differs from the in utero 
environment, this may lead to an increased risk for cardiovascular disease. Studies 
in pregnant rats show that a protein-restricted diet results in reduced expression 
of Dnmt1, leading to hypomethylation of specific promoters.85 These observations 
provide a strong indication that the in utero environment leads to epigenetic (re-)
programming, which later in life might contribute to disease development.
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Epigenetic regulation of cell activity
Cell differentiation (e.g. monocyte differentiation into macrophages) and 
cell-specific gene expression in most cases is controlled by epigenetic mecha-
nisms. Below, the most important cellular factors that contribute to atherosclerotic 
plaque formation and how their phenotype is regulated by epigenetic processes 
will be discussed.
T cells
Several lines of investigation illustrate that T  cells are important in the for-
mation of (early) lesions.86–89 Within the plaque, several subsets of T cells can be 
found. Mainly CD4+ T cells are dominantly found in plaques, but there are some 
CD8+ T cells found as well.5 The T cells present in human plaques are predomi-
nantly of the Th1 phenotype.89 Th1 cells produce IFN-γ – a macrophage activating 
cytokine – and are generally considered pro-atherogenic. Th2 cells are rarely de-
tected in lesions.90 They are generally considered anti-atherogenic, but may also 
contribute to aneurysm formation.91 Regulatory T cells (Treg cells) control the bal-
ance between Th1 and Th2. Tregs are considered to be atheroprotective.92
All T cells derive from the same precursor: the naïve T-cell. Not surprisingly, 
differentiation of e.g. CD4+ T cells into a Th1, Th2 or Treg phenotype is regulated 
by epigenetic processes.93,94 The differentiation of naïve T cells into Th1 or Th2 is 
determined by IL-12 and IL-4 cytokines respectively. In response to these signals, 
transcription is initiated of lineage specific cytokine genes including IFN‑γ and 
IL‑4.95 The IFN‑γ and IL‑4 loci are maintained in a poised state in naïve T cells, mean-
ing they show both repressive and activating epigenetic marks. In 1998 it was first 
proposed that epigenetic, chromatin-based structural changes, underlie the Th1/
Th2 differentiation.96 These epigenetic mechanisms – that are necessary to stably 
maintain gene expression patterns and eliminate the need for feedback loops – will 
be discussed below.
In Th1 cells expression of IFN-γ is preceded by remodelling of the IFN‑γ locus.97 
Upon initial stimulation of naïve T cells, the lineage determining factors GATA3 and 
T-bet mediate many of the structural changes to the chromatin.93 These factors will 
respectively render the IFN‑γ or IL‑4 genes accessible to regulatory enzymes and 
other transcription factors.98–100 On the level of DNA methylation, there are numer-
ous findings supporting the epigenetic regulation of IFN-γ expression. Increased 
expression of IFN-γ was found in T cells from Dnmt knockout mice101 and in T cells 
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treated with DNMT inhibitors (DNMTi).102,103 In addition, expression of IFN-γ by NK 
and NKT cells is also controlled by epigenetic processes.97 The ability of NK and 
NKT cells to rapidly produce substantial amounts of IFN-γ implies that the IFN‑γ lo-
cus is accessible to transcription factors, meaning that the chromatin at the IFN‑γ 
locus is maintained in an ‘open’ state. Indeed the IFN‑γ locus in NK cells was found 
to be hyperacetylated and in a poised state.104,105
In the differentiation to Th2 cells, IL-4 expression is preceded by remodelling of 
the IL‑4 locus, similarly to the IFN‑γ locus remodelling in Th1 cells. In naïve T cells, 
the IL‑4 locus is ‘poised’, allowing rapid, early transcription. The IL-4 promoter re-
gion exhibits a low basal level of H3 acetylation and DNA hypomethylation, but also 
shows H3K27Me3 (i.e. triple methylation of lysine 27 on histone H3) modifications. 
When naïve T cells are stimulated under Th1 conditions, transcription activating 
chromatin marks at the IL‑4 locus are replaced with repressive marks, whereas the 
contrary happens under Th2 stimulating conditions (e.g. at the IFN‑γ locus). These 
processes have been excellently reviewed by Ansel et al.106
The Foxp3 transcription factor is considered the master switch for Treg. The pro-
moter of this transcription factor showed difference in methylation levels between 
Tregs and non-Treg CD4+ cells.107 Furthermore, this study also showed difference in 
activating histone marks (H3Ac, H4Ac and H3K4Me3) in FOXP3 promoter chromatin. 
Epigenetic regulation of T cell subtypes has also been shown in vivo. Mice, which 
were treated with the HDACi TSA showed an increase in Foxp3+ CD4+ Treg cells 
– both proportionally as well as in absolute numbers – in the lymphoid tissues.94 
Besides influencing T cell populations, the differentiation of monocytes to dendritic 
cells (DCs) can also be modulated by HDACi.108
Monocytes
Monocytes are critical players in the formation of atherosclerotic plaques. 
Monocytes migrate from the vessel lumen into the arterial wall, where they dif-
ferentiate into either DCs or macrophages (Figure 1–1). These macrophages later 
transform into foam-cells, one of the major components of the atherosclerotic 
plaque. It has been shown by two independent researches that interfering with 
HDAC function during differentiation resulted in the formation of function-impaired 
DCs. Notably, treatment with the HDACi’s butyrate and MS275 resulted in lowered 
expression of CD1. CD1 expression is a marker for mature DCs, but notably it is 
also important in the presentation of lipid antigens and thus may play an important 




Epigenetic mechanisms are also directly involved in the transcriptional regu-
lation of immune genes in the vascular wall. For instance, in cultured human ECs 
it was found that administration of the HDACi TSA inhibited TNF-α induced mono-
cyte adhesion. This was the result of downregulation of the VCAM‑1 gene, however 
ICAM‑1 and E-selectin – two other cytokines inducible genes – where not affected.110 
This suggests that the HDACi modulated TNF-α–mediated signalling specifically 
targets the VCAM‑1 promoter, instead of general inhibition of the NF-κB pathway. 
This notion is interesting, since NF-κB is a target for chromatin modifying enzymes 
as well (see “Non-histone Targets” on page 31). Similar results have been pre-
sented for the induction of tissue factor in human ECs. The human tissue factor (TF) 
promoter contains an NF-κB–related binding site: TF-κB. HDACi administration 
inhibited agonist induced (TNF-α, IL-1β or LPS) TF activity in ECs by blocking ac-
tivation of TF-κB (TF activity was reduced 90% in HUVEC; 50 % reduced in PBMC, 
in vitro). TSA nearly abolishes TF-κB binding, without affecting NF-κB binding (as 
determined by electrophoretic mobility shift assays (EMSAs), chromatin immuno-
precipitation (ChIP) and luciferase promoter reporter assays). These results were 
achieved using a variety of structurally distinct HDACi’s.111
Work performed in the group of Stefanie Dimmeler showed an important role 
for HDACs in regulating several endothelial specific genes. Using HDACi’s, it was 
shown that Endothelial Nitric Oxide Synthetase (eNOS) mRNA and protein levels 
decreased after HDACi administration.112 Furthermore the ‘master-switch’ for 
some typical endothelial expressed genes (HOXA9, which regulates eNOS, VEGF 
receptor 2 and VE-cadherin expression) was also downregulated in its expression 
by HDACi administration.113
Smooth Muscle Cells
The data reported in literature regarding epigenetic regulation in SMCs provides 
an explanation how epigenetics may control lineage specificity. Nearly all SMC-
restricted protein genes contain the CArG box DNA sequence within their promoter 
and this sequence is also required for SMC gene transcription in vivo. Genes impor-
tant for SMC phenotypic switching (e.g. genes important for migration, proliferation 
and ECM production) also contain CArG boxes within their promoters.114 CArG boxes 
serve as a binding site for Serum Response Factor (SRF), a transcription factor.115 
However SRF expression is not limited to SMCs and serves many functions in dif-
ferent cell types including cell migration and cell-cell adhesion.116
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Multiple pieces of evidence suggest that SRF binding to CArG boxes in SMCs 
is regulated at the level of the chromatin structure. First of all, the x-ray crys-
tal structure of SRF showed that SRF requires several contacts within the minor 
groove of DNA. The minor groove would be obscured if DNA was wrapped around 
the nucleosome structure. Also from thermodynamic considerations, binding of 
SRF to the CArG box would be greatly inhibited if the CArG box was bound to nucle-
osomes (see McDonald et al.117 and references therein).
Secondly, using EMSAs it was shown that SRF can bind to synthetic DNA with 
the same affinity as to DNA obtained from lysates of both SMC and non-SMC cell 
cultures. Conversely, by using ChIP assays, it was shown that SRF binds to promot-
er regions in SMCs much more effectively then to promoter regions in non-SMCs. 
This suggests that in SMCs the chromatin is in such a state that it is accessible 
to SRF.118–121 This observation is supported by micrococcal nuclease digestion ex-
periments, which showed that the CArG box of gene promoters in SMCs is more 
accessible to digestion then in non-SMCs.122
Finally, it was shown that histone H3 and H4 acetylation was increased in SMCs 
when compared to numerous different cell-types, including cultured endothelial 
stem cells. In addition, non-SMCs where enriched for the repressive chromatin 
marks H3K27Me3 and H4K20Me2 at SMC-specific promoter regions (see McDonald 
et al.117 and references therein).
Evidence from diabetic mouse models suggests an important role for epige-
netic regulation in the inflammatory phenotype of vSMCs. The recently discovered 
KDM, lysine-specific demethylase (LSD-1 or KDM1, a H3K27Me2 demethylase), 
was shown to play a role in the pro-inflammatory phenotype of vSMCs in diabetic 
mice.123 In this mouse model levels of H3K4Me2 (a histone modification correlated 
with expression) were increased at the MCP-1 and IL-6 promoter. Upon stimula-
tion with TNF-α there was recruitment of RNA polymerase II to the promoter and 
increased expression of MCP-1 and IL-6. Expression of LSD-1 was shown to be de-
creased in vSMCs. Knockdown of LSD-1 with siRNA increased inflammatory gene 
expression whereas over expression decreased inflammatory gene expression in 
vSMCs of these mice.
It may very well be possible that similar mechanisms apply in the case of ath-
erosclerosis. As discussed in a previous section, vSMCs isolated from rat thoracic 
aorta, which were treated with the HDACi TSA, displayed an inhibition of vSMC 
proliferation.82 It was subsequently shown that expression of p21WAF1 was induced 
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by this treatment. However, HDACi treatment had no effect on SMCs isolated from 
p21WAF1 knockout mice.
Together, these findings illustrate how epigenetic mechanisms play an important 
role in the processes that control differentiation and activation of hematopoietic 
cells, but also of vECs and vSMCs.117,124
Chemokines, their receptors and other genes involved in 
inflammation
Expression of immune response genes in vECs and vSMCs is a major deter-
minant in atherosclerosis onset and development because it contributes to the 
vascular-immune crosstalk. The vascular wall modulates inflammation by the 
expression of numerous cytokines and chemokines. For many of these genes epi-
genetic components, influencing expression, have been identified. Below, some of 
the best-studied examples will be discussed in detail.
eNOS
As stated in the previous sections, many inflammatory processes are recog-
nized by an epigenetic component. One of the best-studied cases of epigenetic 
regulation in the vascular wall involves the transcription of eNOS, an enzyme which 
is regarded as endothelial specific. Its catalytic product, Nitric Oxide (NO), was 
first identified as a vasodilator,125 although recent evidence also suggest a role 
in inflammation. NO has been attributed roles in leukocyte adhesion and vSMC 
proliferation.126 Furthermore, dysfunctional eNOS is believed to be implicated in 
atherosclerosis development.127
The human eNOS promoter does not contain a canonical TATA box, nor does 
it contain a proximal CpG island. Expression of eNOS is restricted to ECs in vivo. 
Various assays in both expressing and non-expressing cell types showed that a 
majority of the non-expressing cell types demonstrated transgene promoter activ-
ity.128–130 In eNOS expressing ECs, eNOS promoter DNA was only slightly methylated 
or unmethylated, whereas non-expressing cells showed a high amount of DNA 
methylation. Treatment of non-expressing cell types with 5-azacytidine (a DNMTi) 
led to an increase in eNOS mRNA levels.130 Later experiments showed the involve-
ment of histone modifications in the expression of eNOS as well. ChIP showed 
enrichment of H3Ac, H4Ac and H3K4Me(2/3) in chromatin of the eNOS promoter 
in eNOS expressing cells. Treatment of non-expressing cells with the HDACi TSA 
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– effectively increasing histone acetylation – also led to an increase in eNOS mRNA 
(See Fish et al.126 and references therein).
iNOS
Not only is eNOS regulated by epigenetic mechanisms, of interest is the ob-
servation that also Inducible Nitric Oxide Synthase (iNOS) is actively regulated by 
the epigenetic mechanisms.131 This gene is expressed in macrophages, but also 
in ECs and vSMCs, under inflammatory conditions. It has been suggested that NO 
– derived from macrophages expressing iNOS – can result in apoptosis of vSMCs, 
promoting plaque instability.132 A study performed by Mellott et al. showed that cy-
tokine induction of iNOS resulted in a change of chromatin structure at the iNOS 
promoter.9 Later work showed that the NOS2A gene, encoding iNOS, had high lev-
els of DNA methylation and of the H3K9Me2 and H3K9Me3 repressive marks in 
non-expressing cells. Cell lines capable of iNOS induction had lower levels of CpG-
methylation and histone 3 lysine 9 methylation at the NOS2A promoter. Treatment 
with a DNMTi resulted in an increase of iNOS mRNA.131
CCR5
CCR5 is important for plaque formation as it attracts T cells and mononuclear 
cells. CCR5 knock-out mice show less neointima formation and an increase in pro-
duction of the anti-inflammatory IL-10 molecule by SMCs.133,134 One of the ligands for 
the CCR5 receptor, CCL5 or RANTES, has also been shown to be involved in unsta-
ble angina pectoris (UAP).135 UAP is generally the result of erosion or rupture of an 
atherosclerotic plaque. CCR5 is epigenetically regulated in T cells. In naïve T cells, 
lacking CCR5 expression, DNA of the CCR5 receptor is hypermethylated and the 
acetylation-level of histone-tails is strongly reduced in CCR5 promoter chromatin. 
When T  cells are activated and express CCR5, DNA-methylation is significantly 
lowered combined with an increase in histone acetylation modifications. These re-
sults are extensively discussed in chapter 3.
The observations above indicate that epigenetic mechanisms play a key role 
also in regulation of (immune) genes in cells that participate in atherosclerosis 





In human atherosclerotic plaques, the chemokine CCL11 (also known as eo-
taxin) was shown by immunohistochemistry to be expressed.136 In healthy tissue 
only negligible amounts of CCL11 were found. Polymorphisms within the CCL11 
gene are also associated with the development of restenosis after PCI.137 CCL11, 
an eosinophil chemoattractant, has been suggested to play a role in atheroscle-
rosis development, although the precise relation remains to be elucidated.136,138,139 
At the same time, CCL11 is expressed by SMCs, while macrophages in the human 
atherosclerotic plaque express the CCL11 receptor, CCR3.136 CCL11 transcription is 
induced by inflammatory TNF-α signalling and is mediated through NF-κB. TNF-α 
induces acetylation of histone H4 in the CCL11 promoter. This results in an open 
chromatin structure, promoting subsequent binding of the NF-κB subunit p65 to 
the CCL11 promoter (as shown by ChIP).140 Notably, glucocorticoids repress CCL11 
transcription through selective inhibition of histone H4 acetylation.140 Although only 
histone H4 acetylation and no other epigenetic markers were investigated, this 
research provides a very strong indication for epigenetic regulation of the CCL11 
gene.140
Epigenetics in (Vascular) Inflammation
KDM6B
De Santa et al. recently showed that inflammation and Polycomb-mediated gene 
silencing are linked.141 Polycomb Group (PcG) proteins are important for the main-
tenance of a repressive chromatin that is stable over many cell divisions. As such, 
PcG proteins play a critical role in differentiation processes and maintenance of 
cellular identity. Gene silencing is mediated by the Polycomb Repressive Complex 2 
(PRC2) through the H3K27Me3 chromatin mark, which is subsequently read by the 
PRC1 maintenance complex (reviewed by Kohler et al.142).
The JmjC-domain protein Jmjd3 (KDM6B, a H3K27 demethylase) is expressed in 
macrophages upon stimulation with bacterial products and pro-inflammatory cy-
tokines.141 Jmjd3 binds to Polycomb Group (PcG) target genes, regulates H3K27Me3 
levels and therewith their transcriptional activity.143 For the first time, an induci-
ble enzyme was shown to erase epigenetic modifications. Later work showed that 
70% of lipopolysaccharide-inducible genes in macrophages are Jmjd3 targets.144 
This provides an essential link between inflammation and reprogramming of the 
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epigenome and might prove to be of vital importance in chronic inflammation and 
autoimmune diseases, including atherosclerosis, in the near future.
Oestrogen receptor 
Oestrogen receptors (ERs) are present in the coronary arterial wall on both 
SMCs and ECs.145–147 ERs may play an important role in protection against ather-
osclerosis.146 Deficiencies in oestrogen receptor alpha (ER-α) lead to accelerated 
atherosclerosis in men, furthermore ER-α mediates the loss of expression of some 
cytokine induced cell-adhesion molecules (see Miller et al.148 and references 
therein). ER-α was shown to have a varying degree of methylation throughout the 
cardiovascular system.149 In the same study it was shown that an age related in-
crease of methylation occurred in the right atrium. Furthermore, higher degrees of 
methylation were found in coronary atheromas when compared to macroscopically 
normal tissues.
Similarly, the oestrogen receptor beta (ER-β) also displays a correlation in 
methylation of its promoter and atherosclerosis.150 Contrary to ER-α expression, 
expression of ER-β correlates with atherosclerosis independent of age.151 By com-
paring plaque vs. non-plaque tissue from the same vessels, it was recently shown 
that the ER-β promoter has higher methylation levels in atherosclerotic lesions.150 
In this study, increased expression of ER-β was also observed – in vitro – in ECs 
and SMCs after administration of a DNMTi (5-aza-2′-deoxycytidine) and a HDACi 
(TSA). These experiments provide supporting evidence for epigenetic regulation of 
the ER-β receptor.
COX-2
Another example for the linkage between epigenetics and cardiovascular dis-
ease related inflammation is transcription of the cyclooxygenase-2 (COX‑2) gene. 
TNF-α – as well as several other cytokines – can induce expression of COX-2, a 
protein associated with atherosclerosis development.152 Cytokines (such as TNF-α 
and IFN-γ) can also induce (indirect) changes to the chromatin, allowing effec-
tor-genes to be expressed upon stimulation.9 For COX-2 it was demonstrated that 
mRNA expression and protein synthesis can be repressed in vitro, in cell lines by 
the HDACi’s sodium butyrate (NaBu) and TSA revealing a significant role for epige-
netic components in Cox-2 expression.153 These experiments were performed in a 
colon cancer cell line, and thus need to be confirmed in cells relevant for vascular 
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biology and atherosclerosis (e.g. vECs, vSMCs or monocytes) to extrapolate these 
results to atherosclerosis.
Transcriptional regulation of MHC molecules – the role of CIITA
Constitutive expression of MHC-II surface molecules is restricted to profes-
sional antigen presenting cells (APC) of the immune system. On all other cell types, 
their expressions can be induced in an environment rich in inflammatory cytokines 
– such as the atherosclerotic plaque – or upon activation such as in human T cells.154 
Therefore, under inflammatory, conditions MHC-II molecule expression can be in-
duced on vECs and vSMCs, which normally are not expressing MHC-II.155,156
The ‘master regulator’ of MHC-II expression is the co-activator CIITA (Class 
II Transactivator)157 Within the context of atherosclerosis, CIITA is of importance, 
since it has been shown to be involved in transcriptional regulation of collagen 
type 1.158,159 Collagen 1 is one of the main components of extracellular matrix and is 
essential in cap formation and plaque stabilisation.10
Transcriptional regulation of MHC2TA, the gene encoding CIITA, is mediat-
ed through the activity of four independent promoter units (CIITA-PI through 
CIITA-PIV, Figure 1–3A).160 These promoter units are employed in a cell type- and 
activation-specific manner. In aortic SMCs CIITA-PIII and –PIV are expressed after 
IFN-γ stimulation and CIITA is needed for IFN-γ–mediated repression of collagen 
type 1 genes (COL1A1 and COL1A2).158,159 Furthermore, collagen transcription is also 
repressed by the RFX family proteins. RFX1 only weakly interacts with the unmeth-
ylated collagen promoter, but binds with higher affinity when the promoter is in a 
methylated state.159
In MHC-II transcription, CIITA exerts its transactivating function through pro-
tein-protein interactions with a multi-protein complex, which is comprised of RFX, 
CREB/ATF and NFY (Figure 1–3B).161–163 Together with CIITA, this complex acts 
as an enhanceosome driving transactivation of these genes.161–163 In the MHC-
enhanceosome, CIITA acts as a platform for recruitment of chromatin-modifying 
activities, which include KATs, HDACs and an arginine methyltransferase.164–166 
Interactions of these chromatin-modifying enzymes and CIITA result in higher-order 
structural changes within the chromatin, effectively activating or silencing MHC-II 
gene transcription.165,167 A number of studies now have shown that epigenetic pro-
cesses not only control MHC-II transcription, but also contribute to the activating/
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discussed in the previous 
sections also target non-his-
tone proteins which could 
lead to alterations in func-
tion of the targeted proteins 
or the generation of novel 
epitopes which now can evoke an adaptive (auto-) immune response.170 Especially 
since NF-κB – playing crucial roles in inflammation – is showing up as one of the 
non-histone substrates. Both NF-κB and p53 are acetylated by KAT3A (CBP) and 
KAT3B (p300),171–174 whereas p53 can also be acetylated by KAT2B (PCAF).175,176
As is the case with most genes, transcription of pro-inflammatory cytokine 
genes such as IFN-γ and TNF-α is positively regulated by transcription factors. 
However, these cytokines can also induce changes to the epigenome. Thus not 
only are cytokines under epigenetic control, cytokines themselves induce (indirect) 
changes to the chromatin, allowing effector-genes to be expressed upon stimula-
tion. Activation of the IFN-γ pathway results in activation of e.g. NF-κB. NF-κB is 
found in the cytoplasm of unstimulated cells, together with its inhibitor, IκB, that 
prevents NF-κB from entering the nucleus.177 Upon stimulation with inducers – 
e.g. reactive oxygen species (ROS) and lipid peroxidase products – IκB is rapidly 
degraded via the ubiquitin-proteasome pathway.178,179 Hereupon, NF-κB is trans-
























Figure 1–3.  (A) Organization of the MHC2TA multipromoter 
region. Each promoter (indicated with black 
arrows) transcribes an unique first exon 
(shaded boxes). Transcription start sites 
are indicated with coloured, angled arrows. 
Promoter PI is mainly used for constitutive 
CIITA expression in dendritic cells, whereas 
PIII is mainly used in B cells, activated T cells 
and macrophages. Promoter PIV is mainly 
used for IFN-γ induced CIITA expression in 
non-bone marrow-derived cells. The function 
of PII is still poorly understood. (B) Factor 
assembly on the MHC-II promoter. Shown is 




κB-elements in their promoter.180,181 This process is known to be activated by KATs 
and repressed by HDACs (See Glozak et al.170 and references therein). The p65 sub-
unit of NF-κB is acetylated by KAT3A/B (P300/CBP) at lysines 218, 221 and 310.182 
The acetylated form of p65 shows weak affinity for IκB. HDAC3 in turn deacetylates 
p65, promoting association with IκBα and thereby nuclear export of NF-κB.171 In 
addition to HDAC3, HDAC1 has been shown in vitro and in vivo to deacetylate p53.183
Besides to acetylation, methylation of non-histone proteins has also been 
observed. For example, methylation occurs at lysine 831 of the vascular endothe-
lial growth factor receptor 1 (VEGFR-1), which is di-methylated by Smyd3 (a H3K4 
methy lase).184 The biological function of methylation at lysine 831 is yet to be dis-
covered. These examples perfectly illustrate how epigenetic and inflammatory 
processes are interwoven.
Thesis Outline
As discussed above, epigenetic control is one of the most fundamental reg-
ulatory systems within the cell. Not surprisingly, it fulfils essential roles in the 
regulation of inflammatory and immune responses involved in atherosclerosis pa-
thology (summarized in Table 1–1). Precise determination of histone modifications 
at specific genes might prove its value in understanding gene expression profiles 
in vascular disease. Especially since small molecules can inhibit the function of 
histone modifying enzymes, altering the expression of genes. Therefore, modula-
tion of epigenetic gene regulation might prove to be the therapeutic intervention of 
the future, especially in complex multi-factorial diseases such as atherosclerosis, 
multiple sclerosis and rheumatoid arthritis.
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Table 1–1:  Overview of genes regulated by epigenetic processes involved in atherosclerosis 
development. Genes for which evidence of epigenetic regulation is solely based 
on administration of inhibitors of histone modifying enzymes are not shown.
Gene Type of Regulation Reference
ec-sod DNA Methylation 74
c-fos Histone Code 80
CD36 Histone Code 81
IFN-γ DNA Methylation & Histone Code 97–99
IL-4 DNA Methylation & Histone Code 106
Foxp3 DNA Methylation & Histone Code 94,107
eNOS DNA Methylation & Histone Code 126,130
iNOS DNA Methylation & Histone Code 9,131
CCL11 Histone code 140
CCR5 DNA Methylation & Histone Code 185
oestrogen receptor α DNA Methylation 149
oestrogen receptor β DNA Methylation & Histone Code 150
CIITA DNA methylation & Histone Code 164–169
In atherosclerosis much information has been gathered over the years regard-
ing the individual components involved in plaque formation as discussed above. 
Systematic investigation however, of epigenetic phenomena in atherosclerosis has 
so far only been conducted in mouse models.186,187 In chapter 2 epigenetic modifica-
tions in human plaques are examined. The plaques investigated are cross-sectional 
for disease pathology. Subsequently, epigenetic regulation of monocytes is inves-
tigated in chapter 3. The transcriptional patterns of the genes encoding epigenetic 
modifying enzymes where studied during the differentiation of monocytes in mac-
rophages and DCs. In chapter 4 interventions by small molecule inhibitors is 
discussed by studying the transcriptional regulation of the CCR5 gene. Chapter 5 
illustrates the interplay between genetic and epigenetic code and discusses a SNP 
found in the upstream promoter region of the epigenetic modifying enzyme PCAF. 
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2AbstractAims:Alterations in epigenetic processes are frequent-ly noted in human disease. These epigenetic processes involve methylation of DNA and post-transla-
tional modifications of histones. It is well established that 
in particular histone methylation plays a key role in gene transcription. In this 
study, we have investigated the relationship between triple methylation of lysine 
27 in histone H3 (H3K27Me3) modifications and atherosclerotic plaque stage.
Materials and Methods:
28 peri-renal aortic tissue patches covering the entire spec-
trum of atherosclerotic plaque development were evaluated by 
immunohistochemistry for the levels of H3K27Me3, EZH2, JMJD3 and BMI1.
Key Findings:
The results of our studies are in support of a reduction in glob-
al levels of the H3K27Me3 modification in vessels with advanced 
atherosclerotic plaques. This reduction in H3K27Me3 levels is not accompanied by 
alterations in global levels of the corresponding histone methyltransferase EZH2, 
the catalytic subunit of the polycomb repressive complex 2 (PRC2). Likewise no 
alterations in global levels of BMI1, a component of the PRC1 complex, which binds 
to H3K27Me3-modified histones or the global expression levels of the histone 
demethylase JMJD3, which removes the methyl marks on H3K27, were observed.
Significance:
Together, our data show that in atherosclerosis development alterations in global 
levels of H3K27Me3 occur. The reduction in the number of nuclei in the tunica media 
that display the repressive H3K27Me3 mark in vessels with advanced atheroscle-
rosis plaques therefore could be a reflection of the dynamic pattern of smooth 




Risk factors for atherosclerosis include many environmental factors.1 Not sur-
prisingly, research over the past few years has focused on epigenetic contributions 
to the disease. Nowadays, we are fully aware of the important involvement of epi-
genetic processes in the regulation of gene expression (see Geissmann et al.2 and 
references therein). Understanding these epigenetic processes is critical for our 
understanding of inflammatory responses and disease.
Epigenetic mechanisms change the accessibility of chromatin.3 The effect of 
these epigenetic processes on transcription depends on the presence of various 
post-translational histone modifications, commonly referred to as the histone code. 
Epigenetic gene regulation is a dynamic process, although the post-translation-
al modifications themselves are chemically stable. Proteins that put the histone 
code in effect can be divided into three classes: ‘writers’, ‘erasers’, or ‘readers’. 
One of the well-studied post-translational histone modifications is triple methy-
lation of lysine 27 in histone H3 (H3K27Me3), which is linked with transcriptional 
repression.4 Loss of H3K27Me3 is associated with cell proliferation (see Moore et 
al.4 and references therein). Gene silencing via H3K27Me3 is orchestrated by two 
protein-complexes: the polycomb repressive complex 2 (PRC2), the silencing ini-
tiation complex, and the polycomb repressive complex 1 (PRC1); the maintenance 
complex.4
The PRC2 core consists of a number of proteins with enhancer of zeste ho-
molog 2 (EZH2) as the catalytic subunit.5 As such, EZH2 has been associated with 
X-inactivation, germline development, stem cell pluripotency, cancer metastasis 
and cell proliferation.6,7 The PRC1 complex consists of (amongst others) chromo-
box homolog (CBX) 2, 4, 6, 7, 8 and B lymphoma Mo-MLV insertion region 1 homolog 
(BMI1; see Mestas et al.5 and Jonasson et al.8 and references therein). This complex 
recognizes the H3K27 trimethylation mark via the chromodomain of the CBX pro-
teins, but does not possess methyltransferase activity itself.8 Although the exact 
function of BMI1 is still unknown, it has been suggested that H2A ubiquitylation 
regulates BMI1-mediated gene silencing.8 Furthermore, reduced expression of 
BMI1 is associated with cellular senescence.9
The histone demethylase jumonji domain containing 3 (JMJD3) removes methy-
lation marks from H3K27.10 JMJD3 has previously been found to be upregulated 
under nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) me-
diated inflammatory conditions, providing a link between epigenetic regulation and 
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inflammation.11 Furthermore JMJD3 has been found to be upregulated in mac-
rophages after lipopolysaccharide (LPS) exposure.11,12 In general polycomb group 
(PcG) proteins are broadly expressed; their expression however, can be modulated 
by environmental stimuli, thus linking extracellular cues to reprogramming of the 
epigenome.13,14
By using immunohistochemistry (IHC), a recent study in ApoE knockout mouse 
identified histone lysine methylation marks as contributing factors to atheroscle-
rosis development.15 In particular, these studies revealed a significant decrease in 
vSMCs for global H3K27Me3 levels in ApoE+/– mice from ApoE-deficient mothers 
when fed with a high cholesterol diet. The effect of post-natal high cholesterol diet 
on global H3K27Me3 levels was also noted when offspring from wild-type mothers 
and ApoE-deficient mothers were compared.15
At the moment, not much is known on the role of epigenetic mechanisms to the 
pathology of atherosclerosis in humans. In the current study, we therefore have 
evaluated global H3K27Me3 levels in vessels representing different stages of ath-
erosclerotic plaque development. Furthermore, we also investigated global levels 
of the writer, eraser and reader of this repressive histone mark in these ather-
osclerotic vessels. Using IHC with antibodies directed against H3K27Me3, EZH2, 
BMI1 and JMJD3, and an automated evaluation method we found that the numbers 
of nuclei that display the H3K27Me3 mark in vessels with more advanced athero-
sclerotic plaques were reduced. The global decrease in the number of H3K27Me3 
immunopositive nuclei in the tunica media reveals the different epigenetic states of 
these cells during progression of atherosclerotic disease.
Materials and Methods
Donor and Tissue sampling
A total of 28 peri-renal aortic tissue patches were studied. The patches were 
obtained during clinical organ transplantation, as has been described previously.16 
The formalin fixed, paraffin embedded sections where cut in 4 µm thick consec-
utive slides. Donor age ranged from 12 to 71 years (Table 2–1). Sample collection 
and handling was performed in accordance with the guidelines of the Medical 
and Ethical Committee in Leiden, the Netherlands and the code of conduct of 




Table 2–1:  Classification of aortic tissue according to the classification of the 




0 (normal vessel) 42 1 2
1 14 1 2
2 50 3 2
3 55 3 1
4 48 1 2
5 57.5 2 2
6 58 5 1
Immunohistochemistry
Slides were deparaffinised in xylene (Merck, Darmstadt, Germany) and rehy-
drated in graded ethanol (Merck) into water. Antigen retrieval was performed in 
0.01M citric acid (Sigma Aldrich, Zwijndrecht, the Netherlands) buffer, pH 6.0 at 
98°C. Slides were stained with the following antibodies against: H3K27Me3 and 
H3K9Me3 (both repressive histone marks), H3Ac and H3K4Me3 (both active his-
tone marks), EZH2, JMJD3, BMI1, or isotype control (Table 2–2). Depending on the 
antibody, slides were permeabilized, pre-blocked by human serum (HS) incubation, 
and/or avidin/biotin-block (Vector Laboratories, Burlingame, CA, USA; Table 2–2). 
Permeabilization was performed by 5 min. incubation in 0.5% (v/v) Triton® X-100 
(Sigma Aldrich) in phosphate buffered saline (PBS), followed by 10 min. incuba-
tion in 0.1M glycine in PBS. Pre-blocking with HS (LUMC Pharmacy, Leiden, The 
Netherlands) was performed by incubating slides for 1h in 5% HS (v/v) in PBS with 
0.05% (v/v) Tween® 20 (Sigma Aldrich; PBS-T). Avidin/biotin block (AB block) was 
performed according to manufacturer’s instructions. Primary antibody incubations 
were all performed overnight in 1% (w/v) bovine serum albumin (Sigma Aldrich) 
in PBS-T unless noted otherwise. Either goat anti-rabbit (Vector Laboratories) or 
horse anti-mouse (Vector Laboratories) biotin conjugate was used as secondary 
antibody, depending on the species (Table 2–2). The secondary antibodies where di-
luted in PBS-T with goat or horse normal serum (Vector Laboratories; dilution 1:66). 
Secondary antibody incubation (1h) was followed by incubation with Vectastain ABC 
(Vector Laboratories). Visualization was performed using 3–3′-diaminobenzidine 
tetrachloride (DAB; Sigma Aldrich) and Mayer’s haematoxylin (Sigma Aldrich) was 
used for counterstaining.
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Image Analysis
Complete slides where digitized with a digital (microscopic) Mirax slide Scanner 
system (3DHISTECH, Budapest, Hungary) equipped with a 20× objective with a nu-
merical aperture of 0.75 and a Sony DFW-X710 Fire Wire 1/3″ type progressive 
SCAN IT CCD (pixel size 4.65 × 4.65 µm). After scanning the locations of the tunica in‑
tima, tunica media and tunica adventitia were annotated by hand using the Panoramic 
Viewer software (3DHISTECH) and exported in the TIFF image-format. The total 
number of nuclei and the number of positive cells for each slide where counted in 
an automated fashion using ImageJ (available at http://rsbweb.nih.gov/ij/). Briefly, 
the algorithm is as follows: slides where separated into haematoxylin and DAB 
components using the colour deconvolution plugin of Ruifrok and Johnston.18 The 
MultiThresholder, with parameter settings “Triangle apply”, was used to thresh-
old both the DAB and the haematoxylin specific images. Potential nuclei where 
identified using particle analysis and subsequently mapped to the haematoxylin 
counterpart. Nuclei consisting of both DAB and haematoxylin components where 
considered as positively stained nuclei, thus eliminating possible background 
staining. The total number of nuclei was counted using particle analysis on the 
haematoxylin image.
Statistical analysis
The relative numbers of positively stained cells are represented as average 
±SEM. The data were analysed using a linear model (ANOVA) with a sex effect, age 
effect, layer effect, AHA (American Heart Association) score effect and interaction 
effects. The analysis was performed in R (R, http://www.rproject.org). All tests 
were performed using t– or F-tests as appropriate. To correct each test for mul-
tiple testing a Bonferroni correction was used. Differences were considered to be 
significant if p < 0.05 after multiple testing correction. Correlations were tested us-
ing Pearson’s correlation based on the total percentage of positive stained nuclei 
per slide and no discrimination was made between tunica media, tunica adventitia 
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Results
Distribution of H3K27Me3, EZH2, BMI1 and JMJD3 in the vessel wall
H3K27Me3, EZH2, BMI1 and JMJD3 staining was performed on serial cross-sec-
tions of 28 different aortic samples. The tissue samples were collected during 
clinical organ transplantation as has been described previously.16 Donors varied 
in age from 12 to 71 years old and samples were specially chosen to cover all sta-
dia (including 3 normal, stage 0, vessels) described by Stary et al. (Table 2–1).17 
Representative staining patterns of normal vessels (stage 0) and vessels with 
advanced atherosclerotic plaques (stage 6) are shown in figure 2–1. It can also 
be established that the staining appears not homogeneous across the entire sec-
tion (Figure 2–2). Especially in the tunica media, positive staining cells are focally 
observed (Figure 2–2). Interestingly, this patchy staining does not show any corre-
lation to plaque size or location of the plaque. The presence of these clusters of 
positive cells most likely reflects different chromatin states within the vessel wall.
The number of stained nuclei was determined following digitization of the slides. 
The tunica intima, tunica media and tunica adventitia were exported as separate im-
ages and by using the ImageJ software package the percentage of positive stained 
cells was subsequently counted, using an algorithm that only takes nuclear stain-
ing into account. The results of these analyses show that, when compared with 
the levels of intimal staining, the abundance of BMI1, EZH2, H3K27Me3, JMJD3 is 
significantly more in the adventitia (Figure 2–3). These varying staining patterns 
might be a reflection of the different cellular compositions of the various vessel 
wall components.
Relationship between H3K27Me3 levels and plaque stage
To investigate the relationship of global H3K27Me3 abundance and plaque stage, 
we correlated the percentage of positively stained cells in the complete vessel wall 
to plaque stage. For this purpose we used the lesion stage classification according 
to the AHA as proposed by Stary et al.17 The results of these analyses revealed a 
significant decrease in the number of nuclei that stained positive for the H3K27Me3 
mark in vessels with more advanced lesions (Figure 2–4). Interestingly, in these 
vessels with more advanced lesions there is also a reduction in the number of 
nuclei that stained positively for BMI1 and JMJD3, albeit that this reduction did not 
reach statistical significance (Figure 2–4). The EZH2 levels showed no significant 
difference between vessels with early and late stage plaques (Figure 2–4).
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Since sex is considered a risk factor for atherosclerosis we also evaluated the 
sex effect in our statistical model and found for H3K27Me3 a significant effect 
(p = 0.006; data not shown).
To estimate the specificity of the H3K27Me3 antibody, IHC with antibodies di-
rected against H3K9Me3, H3K4Me3 and H3Ac was also performed in a number of 
cases. Both H3K9Me3 and H3K27Me3 are associated with transcriptional repres-
sion whereas H3K4Me3 and H3Ac are associated with transcriptional activation. 
0
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Figure 2–1.  Representative staining for BMI1, EZH2, H3K27Me3, JMJD3 (upper panel) and their 
respective isotype controls (lower panel) staining in a normal vessel (stage 0) and an 
advanced plaque vessel (stage 6). Scale bars indicate 100 µm.
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Shown in figure 2–5 (upper panel), is the staining pattern for H3K4Me3, H3Ac, 
H3K9Me3 and H3K27Me3 in vasculature-associated lymphoid tissue (VALT). Since 
VALT has a higher cell density, staining patterns are more easily discriminated. The 
staining patterns for H3K4Me3 and H3Ac marks are noticeably distinct from the 
H3K27Me3 and H3K9Me3 marks. Staining patterns for H3K9Me3 and H3K27Me3 
show more similarities, but still yield a distinctively different pattern.
Figure 2–2.  Representative slide showing nuclear H3K27Me3 staining in a normal vessel (stage 
0) of a 16–year-old female. Staining is non-homogeneous throughout the vessel wall. 
Differential staining-patterns can clearly be observed between the tunica intima, 




Besides assessing VALT, the 
tunica media of vessels was also as-
sessed to estimate the specificity 
of the H3K27Me3 antibody used in 
IHC. The staining for H3K4Me3, H3Ac, 
H3K27Me3 and H3K9Me3 yield patterns 
distinctive from each other (Figure 2–5, 
lower panel), although it is harder to 
visually discern the staining pattern 
in the tunica media compared to in 
VALT. Together, these distinct staining 
patterns reflect the specificity of the 
H3K27Me3 antibody for detecting the 
H3K27Me3 histone mark.
To further define the vessel wall 
components driving this change in 
global H3K27Me3 abundance, we in-
vestigated the distribution of this mark 
across the various vessel layers and 
plaque stage. As revealed in figure 
2–6 all three layers showed lower levels in the number of nuclei displaying the 
H3K27Me3 mark. However, the reduction in the global levels of H3K27Me3 was 
more pronounced in the tunica media of vessels with late stage atherosclerotic 
plaques. The numbers of nuclei that reacted with the anti-EZH2, anti-JMJD3 and 
anti-BMI1 antibodies in the various vessel wall components remained similar in 
vessels with early and vessels with late stage atherosclerotic plaques (data not 
shown).
Correlation between H3K27Me3 levels and BMI1, EZH2 and JMJD3 levels
Given the functions of EZH2, JMJD3 and BMI1, a correlation between H3K27 Me3 
levels and EZH2, JMJD3 and BMI1 levels can be expected. Correlations between 
the various staining levels were tested using Pearson’s correlation. We found a 
weak correlation between levels of H3K27Me3 and BMI1 (p = 0.014; r = 0.494; Figure 





























Figure 2–3.  Percentage of positive nuclei found 
in tunica intima, media or adventitia. 
A significant increase of positively 
stained cells can be found in the 
tunica adventitia when compared 
with the intima, regardless of the 
used antibody. Error bars indicate 
±SEM.
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Discussion
Currently it is widely appreciated 
that epigenetic processes contribute to 
disease pathogenesis including ather-
osclerosis. This is illustrated by recent 
research, which showed global alter-
ations in DNA methylation in patients 
with CVD.19–21 Some studies have also 
shown effects of small molecule in-
hibitors that interfere in the activities 
of histone modifying enzymes on dis-
ease parameters such as plasma 
cholesterol levels (see Wierda et al.2 
and references therein). In a previous 
study from our institute using the ApoE 
mouse model, an association between 
histone methylation and diet-induced 
hypercholesterolemia in vSMCs of 
ApoE+/– offspring from ApoE-deficient 
mothers was revealed.15 In particular a 
significant decrease in vSMCs for global 
H3K27Me3 levels was noticeable fol-
lowing a high cholesterol diet postnatal 
in these ApoE+/– offspring.15 A similar 
effect of this diet was also noted on global H3K27Me3 levels when offspring from 
wild-type mothers and ApoE-deficient mothers were compared.15 To date, nothing 
is known with respect to alterations in global histone methylation patterns in hu-
man atherosclerotic processes. Therefore, in the current study, we have evaluated 
the association of global levels of H3K27Me3 with varying grades of atherosclerotic 
lesions. The results of this study revealed a significant decrease in the number of 
nuclei that stained positive for the H3K27Me3 repressive mark in vessels with late 
atherosclerotic lesions in comparison to vessels with early lesions. Particularly 
this difference was most pronounced in the tunica media, which comprises mostly 
vSMCs. Similar to the observations made in the ApoE-mouse model, high levels of 
cholesterol may contribute to the observed reduction in H3K27Me3 levels in the 























Figure 2–4.  Quantitative analysis of staining 
patterns. Shown is the percentage 
of nuclei staining positive for 
proteins involved in H3K27Me3 
methylation (i.e. BMI1, EZH2, 
JMJD3) and the H3K27Me3 
mark itself, in early and late 
stage atherosclerotic plaques. 
A significant reduction of the 
H3K27Me3 mark was observed in 




We also studied the association of EZH2, BMI1 and JMJD3 in these atheroscle-
rotic processes. No significant differences were observed in the number of nuclei 
that reacted with the immune reagents against EZH2, BMI1 and JMJD3 between 
vessels with early (including normal vessels) or with late atherosclerotic plaques. 
Therefore, no direct correlations could be made between levels of H3K27Me3 and 
levels of EZH2 (in the context of the PRC2 complex, the writer of the H3K27Me3 
mark), of BMI1 (in the context of the PRC1 complex, the reader of the H3K27Me3 
mark) or with JMJD3 (the eraser of the H3K27Me3 mark). The percentage of immu-
nopositive H3K27Me3 and BMI1 nuclei however does show a significant, albeit weak 
correlation. This provides an indication that the observed change in H3K27Me3 









Figure 2–5.  Specificity of the H3K27Me3 antibody was estimated by IHC staining with antibodies 
detecting other posttranslational modifications in histone H3 in serial sections of 
vasculature-associated lymphoid tissue (VALT) and of the tunica media. Shown in 
this figure are the staining patterns for H3K4Me3, H3Ac, H3K9Me3 and H3K27Me3. 
(Upper panel): Staining in VALT of a vessel with a ruptured plaque (stage 6) of a 
57–year-old male. Since VALT has a higher cell density, staining patterns are more 
easily discriminated. The H3K4Me3 and H3Ac marks (associated with transcriptional 
activation) are notably distinct from the H3K27Me3 mark (associated with 
transcriptional repression). Staining patterns for H3K9Me3 and H3K27Me3, both 
marks being associated with transcriptional repression, show a higher degree of 
similarity. (Lower Panel): Staining pattern in the tunica media in a normal vessel 
(stage 0) of a 16–year-old female; vessel is identical to the vessel shown in figure 2–2. 
The H3K4Me3, H3K9Me3 and H3Ac marks all show a visually distinct pattern from the 
H3K27Me3 mark. Scale bars indicate 50µm.
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The change in global histone modi-
fication levels without a change in the 
associated writer or eraser, observed 
in this study, has been noted before 
as well.22 In a different study it was 
observed that, although EZH2 levels 
were significantly increased between 
patients and controls, there was no 
difference in global H3K27 methylation 
levels in PBMCs of patients with pso-
riasis vulgaris.23 It must furthermore 
be realized that IHC does not address 
the functional activities of the proteins 
investigated or the catalytic capacity of 
the active complexes.
Of interest is the notion that re-
gardless of the antibody used in the 
immunohistochemical staining, there 
is significantly more staining in the 
tunica adventitia. This is most likely a 
reflection of the cell types commonly found in the adventitia, which differ from 
those in the tunica media and tunica intima. A most likely explanation is that (ac-

























Figure 2–6.  Location of H3K27Me3 within 
the vessel wall for early and late 
stage atherosclerotic plaques. A 
reduction of H3K27Me3 levels can 
be observed in all layers of the 
vessel wall. The most pronounced 
reduction of H3K27Me3 can be 
observed in the tunica media. Error 
bars indicate ±SEM.
Figure 2–7.  Correlations between H3K27Me3 levels and BMI1, EZH2 and JMJD3 levels. Correlations 
were tested, using Pearson’s correlation, between the percentage of immunopositive 
H3K27Me3 nuclei and JMJD3, EZH2 or BMI1 immunopositive nuclei. No correlation 
was found between the percentage of H3K27Me3 immunopositive nuclei and JMJD3 or 
EZH2 immunopositive nuclei. A significant, albeit weak, correlation was found between 






































































Interestingly, in vessels with advanced plaque stages, the observed decrease in 
H3K27Me3 positively stained cells occurs mostly in the tunica media. Given the role 
of the H3K27Me3 modification in chromatin condensation and gene silencing, the 
reduction in global H3K27Me3 levels in the tunica media infers that chromatin ac-
cessibility is increased, which could affect also the rate of transcription of genes 
involved in cell proliferation. This may reflect the proliferation of vSMCs commonly 
described in plaque formation. Whether this decrease in global H3K27Me3 levels 
proceeds or follows vSMC proliferation remains to be established.
In previous in vitro studies, a relation was found between cell activation and 
JMJD3 expression in macrophages.11,12 In these studies cultured cells were subject-
ed to LPS stimulation for several hours. Peak JMJD3 expression occurred after 2 
hours whereafter JMJD3 levels diminished, showing that this is a temporary event. 
Both inflammation and macrophages form a central hub in the pathology of ather-
osclerosis. However, neither early, nor advanced atherosclerotic plaques showed 
significant alteration in JMJD3 levels in the various vessel wall components. The 
use of cross sectional material in this present study makes it therefore very un-
likely to encounter macrophages that have been activated in the same time frame 
as in these previous in vitro studies.11,12 Secondly, although macrophages are one 
of the major constituents of atherosclerotic plaques, they are present in relatively 
small numbers when the entire cross-section is taken into account, as in this study. 
Even if the effect observed by De Santa et al.11,12 is present in human atherosclerotic 
plaques, it will probably not be reflected in the type of data we show here. Finally, 
the effect seen in the study by De Santa et al. may have been a LPS-specific effect, 
whereas LPS is not commonly associated with atherosclerosis.
Limitations of the current study
IHC results are notoriously hard to quantify, as staining intensity is not always 
correlated with protein concentration.24 Furthermore DAB staining does not follow 
Lambert Beers Law complicating quantification. Also, DAB and heamatoxillin are 
hard to spectrally unmix by image processing.25 In the data presented here, the 
heamatoxillin staining is often overpowered by strong DAB intensity. Using immu-
nofluorescence the limitation of spectral unmixing could be overcome, but care 
must be taken in correlating intensity to protein expression with regards to quan-
titative analysis. The results presented here would therefore need to be confirmed 
by more quantitative methods, such as western blotting or ELISA. By using such 
methods distribution of protein expression across tissue however will be lost.
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Trimethylation of H3K27 plays a definitive role in random X-chromosome in-
activation26 and lineage determination.27,28 It could therefore be expected that 
all, or at least a large number of cells of female-derived vessels stain positive for 
H3K27Me3 or for the commonly expressed modifying proteins EZH2, JMJD3 and 
BMI1. However, the seemingly low level of immunopositive nuclei that we found 
both in normal and in atherosclerotic vessels is observed quite frequently also in 
other studies. In several studies aimed to evaluate global levels of specific histone 
acetylation and methylation modifications it has been shown, both in humans and 
in mice, that these histone modifications, including H3K27Me3, are not detected in 
the nucleus of every cell by IHC.15,29–31 This seemingly lack of the presence of a spe-
cific histone acetylation or methylation modification in the nucleus could be the due 
to the detection limitations of IHC. However, given the fact that this type of staining 
pattern has previously been observed in IHC,15,29–31 it would be very unlikely that in 
the current study this relates to atherosclerosis pathology.
Conclusion
Our findings reveal the dynamics in the numbers of nuclei that display the 
H3K27Me3 mark during disease progression. The reduction in the number of nu-
clei that display the H3K27Me3 could reflect a phenotype switching of vSMCs. Due 
to sensitivity limitations of the current study, these results need to be confirmed by 
more quantitative methods.
Because epigenetic processes are involved in the transcriptional regulation of 
many, if not all genes, it remains to be elucidated which specific genes whose prod-
ucts contribute to atherosclerosis formation are actively controlled by H3K27Me3 
in these different vSMCs (see Wierda et al.2 and references therein). With many en-
vironmental risk factors contributing the atherosclerosis development, epigenetic 
phenomena may hold the key to understanding the onset and progression of this 
disease. Furthermore, these enzymes may also prove to be effective targets for 
clinical management of the disease, given the wide availability of Small Molecule 
Inhibitors that interfere in the activities of the enzymes that modify histones by 
acetylation or by methylation.
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Monocytes play a key role in immune system function. Chromatin remodeling 
is crucial for various differentiation and gene regulation processes and is rath-
er well studied in T cells. However, for monocytes not much is known regarding 
how the epigenetic machinery influences the differentiation into various effector 
cell types. In the work presented here, we explore the epigenetic underpinnings 
of monocyte differentiation. By transcriptional profiling we show that transcrip-
tion of lysine methyltransferases (KMTs) and in particular KMT1C is markedly up 
regulated after differentiation of monocytes into immature dendritic cells (iDCs). 
Specifically inhibiting KMT1C function, using the small-molecule inhibitor 
BIX-01294, changes the transcription levels of the DC marker DC-SIGN, but does 
not affect surface protein expression. Blocking global KMT activity, using DZNep, 
does influence monocyte differentiation into iDCs, indicated by a loss of DC-SIGN 
surface expression. When BIX-01294 and DZNep treatment was combined DC-
SIGN expression was almost lost completely. This work shows that the activities 
of KMTs are required for successful differentiation of monocyte-derived dendritic 
cells. Furthermore it shows the importance of KMT inhibitors in the field of epi-




Monocytes are key players in the functioning of our immune system. They are 
the precursor cells that upon differentiation form dendritic cells (DCs) and mac-
rophages.1,2 In diseases such as atherosclerosis and multiple sclerosis, monocyte 
dysfunction contributes to a great extend to disease initiation and progression.3 
In atherosclerosis particularly monocytes navigate to sites of endothelial dam-
age, adhere to the vessel wall and transmigrate over the endothelial cell layer to 
infiltrate the underlying tissue.4 When monocyte entry of the subendothelium is 
inhibited, by blocking chemokines or their receptors, atherogenesis is retarded or 
prevented in mouse models.5
Differentiation of monocytes into macrophages is a critical step in the pathogen-
esis of atherosclerosis. Upon transendothelial migration, monocytes differentiate 
into functionally defined subsets: the classically activated or M1 macrophages or 
the alternatively activated or M2 macrophages. Classically activated macrophages, 
a profile induced by Th1 cytokines, mainly display an inflammatory phenotype and 
produce pro-inflammatory cytokines such as IL-6, IL-12 and TNF-α. In contrast, al-
ternatively activated macrophages are induced by Th2 cytokines and display a more 
atheroprotective phenotype, exemplified by the secretion of e.g. IL-10.6 In addition, 
monocytes may also differentiate into DCs, depending on the stimulus.7–9
Dendritic cells, once activated, play an important role in the pathogenesis of 
atherosclerosis and are particularly harmful in destabilizing the atherosclerotic 
plaque.6 Studies of DCs in patients indicate that aberrant DC activation or functions 
are associated with different autoimmune diseases including rheumatoid arthri-
tis, multiple sclerosis, systemic lupus erythematosus, psoriasis, and inflammatory 
bowel disease (e.g. Crohn’s disease and ulcerative colitis).10
How epigenetic regulation potentially influences various pathological conditions 
has been subject of several studies in recent years.11,12 Epigenetic regulation of gene 
expression is thought to regulate lineage-specific gene expression in a manner that 
is stable across cell divisions. In humans, the chromatin remodelling involved in 
T  cell differentiation has been rather well studied.13–16 The epigenetic processes 
underlying differentiation of monocytes into dendritic cells and into macrophages, 
however, have not yet been studied in much detail. The work published on epige-
netic regulation involving monocytes focuses on the epigenetic regulation of single 
genes, including following the response to interferon stimulation.17–19 In addition 
to epigenetic regulation at a single gene level, some studies have been published 
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on genome-wide distribution of epigenetic markers, in particular H3K4me3 and 
H3K27me3.20,21 That epigenetic processes indeed play an important role also in 
monocyte differentiation is also illustrated by the observation that inhibition of HDAC 
activity by the HDAC inhibitor (HDACi) butyrate results in inhibition of functional dif-
ferentiation of human monocyte-derived dendritic cells.22 While all previous work 
has mainly focused on the activity of epigenetic regulatory enzymes, in this study 
we present for the first time the expression characteristics of the genes encoding 
epigenetic regulatory enzymes. The transcription characteristics of these genes 
were measured during monocyte differentiation into various effector cells. By us-
ing specific inhibitors, an important functional role for lysine methyltransferases 
(KMTs) and in particular KMT1C in monocyte differentiation into dendritic cells is 
revealed.
Materials and Methods
Cell isolation and culturing
For the initial screening of transcript levels of epigenetic modifiers, peripheral 
blood was obtained by venipuncture from three individuals undergoing phlebotomy 
at Sanquin (Amsterdam, the Netherlands). For the validation of KMT1C transcript 
levels peripheral blood of institutional volunteers was drawn by venipuncture and 
collected into sodium citrate tubes (Greiner). For both screening and validation 
experiments, peripheral mononuclear cells (PBMCs) were then isolated by den-
sity gradient centrifugation using Ficoll Isopaque plus (GE Healthcare). Written 
informed consent was obtained from all participants. The study protocol conforms 
to the Declaration of Helsinki and was approved by the ethics committees of the 
institutions. Five parts of blood were diluted with one part of buffer consisting of 
phosphate buffered saline (PBS; LUMC Pharmacy) + 10% v/v GPO (Sanquin) + 10% 
v/v Sodium Citrate (LUMC Pharmacy). PBMC fraction was recovered and washed 
three times in buffer. Monocytes were isolated from the PBMC fraction by magnetic 
separation with anti-CD14 magnetic beads (MACS; Milteny Biotech). 
Between 0.25 and 1.0 × 106 freshly isolated monocytes were seeded in 1 mL in 
a 24-wells plate. Cells were cultured in RPMI-1640 medium (Gibco, Invitrogen) 
supplemented with 10% heat-inactivated fetal calf serum (FCS; PAA), 100 IU/mL 
streptomycin, 100 IU/mL penicillin (both Lonza) and 2 mM L-glutamine (Gibco). 
Cytokines were added to the medium to obtain DCs (1000 U/mL GM-CSF, 500 U/
mL IL-4), M1 (50 U/mL GM-CSF) and M2 (50 ng/mL M-CSF) as previously described 
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by Verreck et al.23 When indicated, cells were cultured in presence of lysine meth-
yltransferase inhibitors (KMTi’s): 5 µM 3-Deazaneplanocin A (DZNep, kind gift of 
V.E. Marquez), 5 µM BIX-01294 (Sigma Aldrich) or a combination of BIX-01294 and 
DZNep (both in final concentration of 5 µM). The used concentrations of inhibitors 
are based on the maximum tolerated concentration, allowing for at least 80% via-
ble cells (assessed by eosin staining), when cells were harvested.
After 5 days of culture, fresh medium and cytokines (and inhibitors) were added 
to the cells and the cells were cultured for an additional 2 days. To obtain activated 
macrophages or maturated dendritic cells (mDCs), the fresh medium was supple-
mented with 100 ng/mL (final concentration) LPS at day 5 of culture and cells were 
cultured for an additional 2 days.
RNA isolation and cDNA synthesis
Either directly after isolation, after 24 hours or 7 days of culture, cells were 
scraped of the culture plate and centrifuged for 5 min at 500×g. Thereafter the 
pellet was lysed in RNAbee (Tel-Test) according to manufacturer’s instructions. 
Lysates were stored at 80°C until further processing. Total RNA was extracted 
according to manufacturer’s instructions.
From 1 µg total RNA, cDNA was synthesized using SuperScript III (Invitrogen), 
with random hexamers (Promega), at 50°C for 1 hour according to manufacturer’s 
instructions.
qPCR
Quantitative PCR was performed on a Bio-Rad iCycler 5 with SYBR Green su-
permix (Bio-Rad) and the primers shown in supplementary table 3–S1. For each 
reaction, 125 ng of cDNA and 5 pmol of forward and reverse primer were used 
in a total volume of 25µL. The thermal profile for the PCR reactions was 3 min 
95°C (enzyme activation) followed by [15s 95°C; 30s Tann; 30s 72°C] for 50 cycles. All 
primers were designed for 60°C annealing temperature. For some primers how-
ever, optimal performance was achieved at a higher annealing temperature. The 
used annealing temperatures are shown in supplementary table 3–S1. Primers 
were designed to pick up all splice variants of a given gene, with the use of NCBI 
Primer design tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). All primers 
were tested beforehand to produce only a single amplicon and for a PCR efficiency 
between 90% and 110%. Amplicons were sequenced to confirm the identity of the 
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target sequence. Amplicon length varies between the primer-pairs from 114bp to 
246bp. All PCR reactions were performed in duplo. For the screening experiment, 
transcription levels were normalized against RNA polymerase II (RPII) transcript 
levels. To minimize normalization-induced error, the transcription levels in the val-
idation experiment and BIX-01294 treatment experiment where normalized against 
the geometric mean Cq-value of RPII, Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), β-glucuronidase (GUS), and Hypoxanthine-guanine phosphoribosyltrans-
ferase (HPRT).
Western Blotting
Monocytes were isolated from peripheral blood and in vitro differentiated to im-
mature Dendritic Cells (iDCs), with and without BIX-01294 present in the medium, 
as described on page 73 and harvested after 5 days of culture. From freshly iso-
lated monocytes and iDCs, two independent histone lysates were prepared by acid 
extraction according to Shechter et al.24 Lysates were separated by electrophoresis 
in a 15% Sodium Dodecyl Sulfate (SDS)-Polyacrylamide gel and transferred over-
night to a PVDF membrane at 10V at 4°C. This membrane was blocked with 2% w/v 
Elk (dried skimmed milk; Campina) in PBST buffer consisting of PBS with 1% v/v 
Tween-20 (Sigma-Aldrich) and probed subsequently with anti-Me2K9H3 antibod-
ies (1:5000, Abcam) and anti-mouse-HRP (1:1000, Dako). Antibodies where diluted 
in 0.2% w/v Elk-PBST. To correct for the concentration difference in the loading 
the same blot is stripped at 50°C using a buffer consisting of 2% w/v SDS (Sigma 
Aldrich), 62.5 mM Tris-HCl (Sigma Aldrich) pH6.8 and 0.8% v/v β-mercaptoethanol 
(Sigma Aldrich). After stripping, the blot was rinsed with tap water for 30 min and 
washed extensively with PBST. Thereafter it was probed again with total-H3 anti-
body (1:10000, Abcam) followed by anti-mouse HRP (1:1000, Dako).
Separated proteins were visualized using ECL (GE Healthcare) and recorded 
using radiographic film (Fuji). The films where scanned and multiple exposures of 
each independent experiment were densitometrically analyzed using the ImageJ 
software.25
Flow Cytometry
Monocytes were isolated from peripheral blood and differentiated to iDCs in 
vitro in the presence of BIX-01294, DZNep, a combination of BIX-01294 and DZNep, 
or without inhibitor as described on page 73. After 7 days of culture the iDCs 
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were harvested by scraping of the dish and washed twice in FACS buffer: PBS, 
supplemented with 1% FCS (PAA) and 0.1% Sodium Azide (LUMC Pharmacy). The 
cells were kept on ice during the rest of the procedure. Cells were stained after 
dilution of the antibody in FACS buffer for 45 min. with DC-Sign (Rat Anti-Human 
CD209 APC; eBioscience; clone eB-h209; dilution 1:80) or the appropriate isotype 
control (Rat IgG2a, κ Isotype Control APC; eBioscience; clone eBR2a; dilution 1:80). 
Cells were washed twice in FACS buffer and taken up in 1% paraformaldehyde. 
Hereafter the cells were kept at 4°C until data acquisition. Flow cytometry data 
acquisition was performed on a FACSCalibur flow cytometer (Becton Dickinson) 
using Cell Quest software. Data was analyzed using the FlowJo software package. 
Live cells were selected based on forward and side scatter properties and analyzed 
for CD-209 expression.
Statistics
The relative expression of transcripts is represented as mean ± SEM with prop-
agated errors. Initial screening experiments where analysed with a linear model 
(ANOVA). First, we applied a variance-stabilizing (cube-root) transformation to the 
expression values. Next, we tested for expression differences between cell types 
among specific groups of genes (F-test). To correct for multiple testing, we used the 
inheritance procedure.26 Briefly, this method is applicable to situations where the 
hypotheses that are to be tested can be structured in a tree. Starting from the root 
of the tree (all genes), we proceed to test ever-smaller subsets of genes, until we 
arrive at the leaves of the tree (single genes). The inheritance procedure, guaran-
tees that the family-wise error rate across all tested gene sets does not exceed 5%. 
The analysis was performed in the statistical software R (R, http://www.r-project.
org). Sequential tests were performed following the tree-model depicted in figure 
3–2B. Statistical testing of the validation study was performed using the Graphpad 
Prism software by means of a Mann–Whitney U test. Differences were considered 
to be significant if p < 0.05 after multiple testing correction.
Results
Transcription levels of epigenetic modifiers
To assess the role of epigenetic processes in monocyte differentiation, we stud-
ied the expression profiles of the genes encoding epigenetic regulatory enzymes 
during monocyte differentiation. Monocytes were isolated from peripheral blood of 
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three volunteers and were cultured for 24-hours in medium alone or for a total of 
7 days in the presence of stimuli to induce differentiation into type 1 macrophages 
(M1) and type 2 macrophages (M2) or immature dendritic cells (iDCs). To monitor 
the effect of activation by LPS, after 5 days part of the cell cultures were activat-
ed for an additional 2 days by addition of LPS. Quantitative PCR was performed 
to measure the transcript levels of 51 genes encoding epigenetic regulatory en-
zymes after extraction of total RNA and cDNA synthesis. These genes represent 
the different classes of epigenetic proteins i.e. DNA methyltransferases (DNMTs), 
lysine acetyltransferases (KATs), histone deacetylases (HDACs) and sirtuins, lysine 
methyltransferases (KMTs) and lysine demethylases (KDMs). Additionally, we stud-
ied the expression profile of members of the two Polycomb Repressive Complexes: 
PRC2 (involved in initiation of gene repression) and PRC1 (involved in maintenance 
of repression). The relative transcription levels were normalized against RNA pol-
ymerase (RPII) transcription. Relative transcription levels are shown in figure 3–1 
and supplementary figure 3–S1.
Differential deployment of epigenetic modifiers
To aid in the analysis of transcript levels, the analyzed genes were divided into 
several (sub-)groups based on their biological properties. In a first division, genes 
were classified according to global substrate specificity (i.e. histone acetylation, 
histone methylation or DNA methylation). Within the acetylation and methylation 
groups, genes were then further subdivided into writing or erasing post-transla-
tional histone modifications (i.e. HDACs vs. KATs and KMTs vs. KDMs). Finally, the 
HDACs were further subdivided into the common HDAC classes (i.e. HDAC class I, 




























































































































Figure 3–1.  Heatmap of transcription levels of epigenetic modifying enzymes in M1, M2 iDC and 
activated M1, M2, mDC. Monocytes were isolated from PBMCs of three independent 
donors and differentiated to the depicted cell types in-vitro. All transcription levels 
were normalized to RPII transcription levels. Data is shown as 2log fold-change 
relative to monocytes cultured for 24h. Polycomb components are shown separately, 




II and IV; based on structural properties), and sirtuins of which only SIRT1 was in-
vestigated.27 A schematic representation of these divisions is shown in figure 3–2A. 
Genes who are a member of one of the PRCs were analysed separately. The lysine 
methyltransferase KMT6 is the catalytic subunit of the PRC2 complex (see Figure 
3–2A) and is therefore not analyzed together with other KMTs.
Following differentiation, the transcription levels of the genes encoding the 
enzymes involved in histone methylation as well as histone acetylation were sig-
nificantly altered in M1, M2 and iDC when compared to the expression levels of 
undifferentiated monocytes that were cultured in medium alone. Transcription lev-
els of PcG genes however were not altered by the differentiation stimulus (Figure 
3–2B). Within the group of (de)methylating enzymes both the expression of KMTs 
and KDMs was significantly altered (p = 1.3×10-6 for KMTs and p = 1.7×10-5 for KDMs). 
Within (de)acetylating enzymes, the expression of HDACs was significantly altered 
(p = 0.015), but notably not the transcription levels of KATs. (Figure 3–2B) The alter-
ation of transcription of KATs and HDACs could not be pointed to a specific enzyme 
as none of the individual transcription levels was significantly altered. Although 
HDAC9 transcription was decreased dramatically, this decrease did not reach sta-
tistical significance (Figure 3–3; p = 0.08 by ANOVA, after correction for multiple 
testing). Within the group of KMTs, KMT1C was significantly higher expressed in 
differentiated monocytes then in monocytes cultured for 24h without cytokines 
(Figure 3–2B & Figure 3–3; p = 0.002 by ANOVA, after correction for multiple test-
ing). Maturation or activation of the differentiated cells by LPS did not have an 


































































Figure 3–2.  (A) Classification of epigenetic modifying enzymes into their respective classes used 
for statistical testing. (B) All classes showing significant difference in transcription 
levels (p<0.05 after multiple-testing correction) after differentiation are shown in 
black. The data were tested for expression differences between cell types among 
specific groups of genes (F-test). Correction for multiple comparisons was done using 
the inheritance procedure for tree-structured hypotheses.26
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Validation of KMT1C transcription levels
Given the important role of dendritic cells in various diseases,10 this cell type 
was used for further validation of the findings above. An additional, unrelated, five 
healthy individuals were used in a validation experiment. Furthermore, as 24-hours 
of culture may already induce differentiation of monocytes, we compared imma-
ture DCs (iDCs) after 7 days of differentiation to freshly isolated monocytes instead 
of monocytes that had been cultured for 24 hours.
The transcription levels of KMT1C in this validation experiment are shown in fig-
ure 3–4. A significant increase of KMT1C transcription (p = 0.0159; Mann-Whitney U 
test; M0 median = 24.52, range: 14.42–45.27; iDC median = 49.77, range: 41.24–73.43) 
was observed in iDCs compared to freshly isolated monocytes. This increase in 
transcription in iDC is comparable to the increase observed earlier when the tran-
scription profiles were compared to those of 24h cultured monocytes.




















Naïve Monocytes vs Dierentiated Monocytes
Figure 3–3.  Volcano-plot showing transcript level fold-change (as shown in figure 3–1) and 
their respective p-values. Transcript levels of naïve monocytes were compared to 
monocytes after differentiation. Data was analysed using a linear model (ANOVA) and 




Inhibition of KMT1C impairs 
monocyte differentiation
KMT1C is described to dimethyl-
ate lysine 9 in histone H3 (Me2K9H3).28 
Therefore, to establish whether the 
increase in KMT1C transcription lev-
els also results in altered Me2K9H3 
levels, global Me2K9H3 levels were 
determined by western blot analysis. 
For this purpose, monocytes were 
differentiated in vitro into iDCs for 5 
days. Acid lysates were prepared from 
freshly isolated monocytes and iDCs as 
described on page 75. The results of 
the densitrometric analyses of two in-
dependent lysates are shown in figure 
3–5A. A clear increase of Me2K9H3 lev-
els can be seen in the iDCs compared 
to the levels of Me2K9H3 in monocytes.
To determine the functional conse-
quences of this increase in Me2K9H3, 
monocytes were in vitro differentiated 
into iDCs in presence of the KMT1C-
specific inhibitor BIX-01294. BIX-01294 
was originally identified as a KMT1C in-
hibitor during a chemical library screen 
of small molecules and has previously 
been used in the generation of induced 
pluripotent stem cells.29–31 Although 
BIX-01294 is generally considered as 
a KMT1C (G9a) specific inhibitor, it can 
also inhibit the G9a-like protein (KMT1d).30 The used concentration of inhibitors al-
lowed for at least 80% of viable cells after 5 days of culturing. After 5 days of culture, 
acid lysates where prepared to check for Me2K9H3 reduction by western blotting. 
Addition of BIX-01294 to the culture medium abrogated the increase in Me2K9H3 
levels in iDC after monocyte differentiation and resulted in similar Me2K9H3 levels 































Figure 3–4.  Transcription levels of KMT1C in 
freshly isolated monocytes and 
iDCs after 7 days of differentiation. 
There results presented here were 
obtained in a validation cohort 
(n = 5) to verify the data depicted 
in figure 3–1 and supplementary 
figure 3–S1. KMT1C transcription 
levels are significantly increased 
in the differentiation process 
(p = 0.0159; Mann-Whitney U test; 
M0 median = 24.52, range: 14.42–
45.27; iDC median = 49.77, range: 
41.24–73.43). Expression levels 
where normalized to the geometric 
mean Cq-value of 4 endogenous 
controls (GAPDH, RPII, GUS and 
HPRT); error bars indicate SEM 
with propagated error.
KMT1C in monocyte differentiation
81
The transcription levels of the typical DC-marker DC‑SIGN (CD209) were sub-
sequently determined by qPCR analysis. RNA was extracted from freshly isolated 
monocytes, and iDCs, which were differentiated in vitro for 5 days with and without 
the presence of BIX-01294. Differentiating monocytes into iDCs in the presence 
of BIX-01294 resulted in a marked reduction of DC-SIGN transcript levels (Figure 
3–6). Finally, the surface expression of DC-SIGN of iDCs and iDCs differentiated in 
presence of BIX-01294 was determined by flow cytometry (Figure 3–7). Although 
addition of BIX-01294 resulted in a reduction of DC-SIGN transcripts, surface ex-
pression of DC-SIGN was not altered by addition of this KMT1C inhibitor.
We also evaluated the impact of inhibition of multiple KMTs considering the 
fact that transcription of the entire group of KMTs was significantly altered during 
monocyte differentiation. For the purpose of these investigations we applied the 
lysine methyltransferase inhibitor (KMTi) 3-Deazaneplanocin A (DZNep) during the 
differentiation of monocytes into iDC, which is regarded as a general KMTi.32–34 
Monocytes where therefore differentiated into iDCs in presence of DZNep and a 
combination of DZNep and BIX-01294 and evaluated for cell surface expression of 
DC-SIGN.
Shown in figure 3–7, DC-SIGN surface expression levels were markedly de-
creased in the presence of DZNep. By adding both DZNep and BIX-01294 to the 

















































Figure 3–5.  (A) Reduction of Me2K9H3 levels measured by densitometric analysis of western 
blots. Me2K9H3 was normalized to total H3 to correct for any loading differences. 
The Me2K9H3 ratio was then normalized to the ratio of freshly isolated monocytes. 
Shown are the results of two independent experiments. Error bars indicate SEM with 




indicates that KMT1C has an important 
role in monocyte to DC differentiation 
and seems to act synergistically with 
the other KMTs in the differentiation 
of monocyte-derived dendritic cells 
based on expression of DC-SIGN.
Discussion
The current study shows that 
transcription of the genes encoding 
epigenetic modifying enzymes is mod-
ulated during monocyte differentiation 
into macrophages and into dendritic 
cells. We show that, with the notable 
exception of KATs and PcG genes, all 
major classes of the genes encoding 
epigenetic modifying enzymes are dif-
ferentially transcribed when comparing monocytes to either macrophages (type 
1 and type 2) or to immature dendritic cells. Further stimulation with LPS did not 
alter these expression patterns. Although the KDM, KMT and HDAC classes as a 
whole are differentially transcribed during differentiation, on a single gene lev-
el, only KMT1C was found to have significantly altered transcription levels during 
differentiation of monocytes into various lineages. Blocking KMT1C activity with 
BIX-01294 resulted in a reduction of DC‑SIGN transcripts, while at the same time 
cell surface expression of DC-SIGN was hardly affected. However, surface expres-
sion of DC-SIGN was reduced when applying the general KMTi DZNep. Notably, 
DC-SIGN surface expression was almost completely lost when both DZNep and 
BIX-01294 were present in the culture medium. Together, these data indicate that 
KMT1C plays a role in monocyte to iDC differentiation. Furthermore, the additional 
studies with DZNep and both DNZep and BIX-01294 show that other KMTs are also 
involved in monocyte differentiation into iDC and that they might act synergistically 
with KMT1C in these differentiation processes.
Unfortunately we were unable to correlate the significantly increased levels of 
KMT1C transcripts with protein levels. Of the multitude of commercially available 






















Figure 3–6.  Transcription levels of the DC-
marker DC-SIGN, determined by 
qPCR. The data is normalized 
to the geometric mean of 4 
endogenous controls (GAPDH, RPII, 
GUS and HPRT) and represent as 
fold-change relative to monocyte 
transcription levels. Inhibiting 
KMT1C activity by addition of 
BIX-01294 results in lowered 
DC-SIGN transcription levels.
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transcript levels is also associated with 
a rise in protein levels remains to be 
established. 
Our data, revealing an effect of KMT 
inhibition on DC-SIGN expression, are 
in line with previous work, which has 
established a role for histone methyl-
ation at the DC-SIGN promoter.19 In that 
study however, only H3K4, H3K9 and 
H3K20 triple methylation was studied 
and notably not dimethylation of H3K9.
Using a western blot and densi-
tometry of X-ray film global Me2K9H3 
levels were determined after BIX-01294 
treatment. X-ray film has limited line-
arity35 and the represented data should 
therefore be regarded as qualitative 
instead of quantitative. Although glob-
al Me2K9H3 levels where lowered after 
BIX-01294 treatment concomitant with 
a reduction in DC-SIGN transcript lev-
els, this reduction apparently did not 
affect levels of DC-SIGN cell surface 
expression. The reduction in DC-SIGN 
transcripts also reveals that KMT1C 
contributes to DC-SIGN gene activation during monocyte differentiation. This 
co-activator function of KMT1C has been documented previously.36–38 In addition, 
it could very well be that in the case of monocyte differentiation, methylation of 
non-histone proteins involved in DC-SIGN homeostasis are likely to compensate 
the lowered levels of DC-SIGN transcripts.39,40 Protein surface expression can 
therefore be influenced both transcriptionally and post-transcriptionally by KMTs. 
Furthermore the observed difference in DC‑SIGN transcription could be due to 
complex interactions of other regulatory factors involved in DC‑SIGN transcription 
instead of directly influencing the DC‑SIGN promoter. Thus the precise molecular 
interactions during differentiation remain however to be established.

















GM CSF + IL 4
Figure 3–7.  Determination of DC-SIGN surface 
expression on iDCs by flow cytome-
try. Live cells were selected based 
on forward and side scatter prop-
erties and analyzed for DC-SIGN 
surface expression. Shown histo-
grams are normalized to peak-cell 
count (% of Max). Addition of 
BIX-01294 has little effect on the 
surface expression of DC-SIGN. 
However addition of DZNep clear-
ly reduces the surface expression. 
When DZNep was combined with 
BIX-01294 surface expression of 




The results presented here indicate that the transcription of KDM, KMT and 
HDAC genes are altered during monocyte differentiation. The work performed by 
Wang et al. is interesting in that respect, as they showed that butyrate functionally 
inhibited the differentiation of monocytes into DCs.22 Butyrate is an HDACi with a 
specificity for class I and IIa (i.e. HDAC-4, -5, -7, -9) HDACs.41 Both HDAC and KMT 
transcription levels rise during differentiation and blocking of HDAC or KMT activi-
ty seems to impair differentiation of monocytes into DCs. It would therefore also be 
interesting to see whether KDMi’s will influence monocyte differentiation.
After the successful usage of HDACi as anti-epileptics and in the treatment of 
various cancers,42–44 it has recently become apparent that epigenetic interference 
can be useful as well in the field of immunology and for treatment of autoimmune 
disorders.45 Recently Immunology and Cell Biology ran a special issue on this 
emerging field. From the editorial it was evident that research in this field is mainly 
focused on HDACs and HDACi.46 The work presented here not only underlines the 
potential of epigenetic therapy, but also illustrates that we should look beyond the 
HDAC-horizon.
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Genetic and Epigenetic Regulation of CCR5 
Transcription
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Epigenetic control of CCR5 transcript levels in immune 
cells and modulation by small molecules inhibitors
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The chemokine receptor CCR5 regulates trafficking of immune cells of the lym-
phoid and the myeloid lineage (such as monocytes, macrophages and immature 
dendritic cells) and microglia. Because of this, there is an increasing recognition of 
the important role of CCR5 in the pathology of (neuro-) inflammatory diseases such 
as atherosclerosis and multiple sclerosis. Expression of CCR5 is under the control 
of a complexly organized promoter region upstream of the gene. The transcrip-
tion factor cAMP-responsive element binding protein 1 (CREB-1) transactivates the 
CCR5 P1 promoter. The cell-specific expression of CCR5 however is realized by us-
ing various epigenetic marks providing a multivalent chromatin state particularly 
in monocytes. In this chapter the transcriptional regulation of CCR5 is discussed, 




The CC chemokine receptor 5 (CCR5) regulates trafficking of lymphoid cells 
such as memory/effector Th1 lymphocytes, or cells of the myeloid lineage (e.g. 
monocytes, macrophages, immature dendritic cells) and microglia. As such, CCR5 
is implicated in the pathogenesis of various inflammatory diseases such as ath-
erosclerosis and multiple sclerosis.1–4 Furthermore, CCR5 also functions as a 
co-receptor for HIV-1.5–7 Notably, CCR5 expression is markedly upregulated upon 
T cell activation,8–11 which allows the activated T cells to migrate towards site(s) of 
inflammation.8,12
Upon encountering a pathogen, antigen presenting cells will present the anti-
genic peptide to resting naïve T cells which results in the generation and activation 
of antigen-specific T cells.13,14 After activation, the T cells migrate to the site of in-
flammation, guided by chemokine receptors.15 Similarly, circulating monocytes are 
also attracted to inflammatory sites by chemokine receptors, where they then can 
differentiate into e.g. macrophages or microglia.16–18 Multiple sclerosis and ather-
osclerosis are greatly characterized by inflammatory lesions, consisting of T cells 
and macrophages or microglia.19–21 The chemokine receptor CCR5 has been shown 
to be implicated in the pathogenesis of both of these diseases.22–25
Expression of CCR5 is under the control of a complexly organized promoter re-
gion upstream of the gene. The main transcriptional activity of the CCR5 promoter 
region is contained within the downstream promoter P1.9,11,26 A number of tran-
scription factors have been shown to play a role in CCR5 transcriptional regulation 
(see Wierda et al.27 and references therein). A graphical representation of the CCR5 
promoter organization and transcription factor binding sites is shown in figure 4–2. 
We have previously shown however that the transcription factor cAMP responsive 
element binding protein 1 (CREB-1) is the main transactivating factor for the CCR5 
P1 promoter.26 However, considering the ubiquitous expression of CREB-128, we 
argued that epigenetic mechanisms are also involved in the cell type-specific regu-
lation of CCR5 transcription. In line with this notion is the observation that transient 
promoter-reporter studies in CCR5-deficient Jurkat T leukemia cells revealed that 
the CCR5 promoter-reporter was activated upon transfection.9 This observation 
infers that Jurkat T  leukemia cells contain all the transcription factors required 
for CCR5 transcription, and demonstrates that CCR5 transcription is additionally 
controlled by epigenetic mechanisms.
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Epigenetic mechanisms control the accessibility of DNA for transcription factors 
and are thought to form the basis for cell-to-cell inheritance of gene expression 
profiles.29 Epigenetic mechanisms as such play an essential role in the regulation 
of gene transcription. Epigenetic modifications include methylation of DNA at CpG 
residues and posttranslational modifications of histone tails such as acetylation 
and methylation.30 Together these modifications form a ‘histone code’ – like the ge-
netic code – that controls transcription levels of genes.31 Importantly, modifications 
to DNA and to histone tails have been shown to be functionally linked.32
Well-studied mechanisms that underlie gene repression by histone methyla-
tion involve tri-methylation of histone H3 at lysine 9 (H3K9Me3) and at lysine 27 
(H3K27Me3), and of histone H4 at lysine 20 (H4K20Me3). These modifications are 
catalysed respectively by the lysine methyltransferases (KMTases) SUVAR39H1 
(hKMT1A), Enhancer of Zeste homolog 2 (EZH2, hKMT6), a subunit of the Polycomb 
Repressive Complex 2 (PRC-2), and SUV4-20H1/H2 (hKMT5B/C).33–36 The KMTase 
hSet1 and the MLL genes (hKMT2A/G) catalyses tri-methylation of K4-H3 
(3MeK4H3) and this modification is associated with gene transcription.36,37
In this study we show that induction of CCR5 transcription – upon CD4+ T cell 
activation – correlates with reduced levels of DNA methylation as well as chang-
es in specific histone modifications within the CCR5 promoter. To establish 
whether the found epigenetic profiles are T cell specific, we also determined the 
epigenetic profile in CD14+ monocytes, being of the myeloid instead of the lymphoid 
lineage. It is shown that the CCR5 chromatin status in primary CD14+ monocytes 
correlates with the intermediate transcription levels of CCR5. Furthermore, the 
T-lymphoblastic cell lines studied (Jurkat, Molt-4, HSB-2) do not express CCR5 and 
show a transcriptionally repressive chromatin environment. Moreover, we show 
that pharmacological interference in these epigenetic silencing mechanisms in the 
CCR5-deficient T leukemia cell lines results in the induction of CCR5 expression. 
Together, these data reveal that epigenetic mechanisms play a pivotal role in the 
control of CCR5 transcription.
Materials & Methods
Cell culture and activation
Naïve human CD4+  T  cells were sorted from freshly isolated PBMC using a 
FACSAria Flow Cytometer (Becton Dickinson). Sorted cells were directly used for 
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chromatin immunoprecipitation (ChIP) analysis, RNA extraction and DNA isolation 
for bisulphite analysis. Naïve CD4+ T cells were also activated in vitro as described 
earlier.38 In brief, naïve CD4+ T cells were stimulated with 1 µg/mL phytoheamag-
glutinin (PHA, Remel Europe Ltd.) and 20 U/mL IL-2 in the presence of irradiated 
allogeneic PBMCs (3000 Rad). After 11 days of culture, cells were restimulated the 
same way and after 12 days cells were harvested for ChIP analysis and bisulphite 
sequencing analysis. For RNA-extraction naïve CD4+ T cells were stimulated with 
anti-CD3 and anti-CD28 for 30 min. Thereafter CD4+ T cells were cultured for 48h 
in CFU-EC medium (Stemcell technologies). RNA was isolated with the RNA-Bee 
extraction method (see page 98).
The leukemic T cell lines Jurkat (Clone E6-1; American Type Culture Collection 
(ATCC)) and MOLT‑4 (ATCC) were cultured in RPMI-1640 medium (Gibco, Invitrogen) 
supplemented with 10% heat-inactivated foetal calf serum (FCS; PAA), 100 IU/mL 
streptomycin, 100 IU/mL penicillin (both Lonza) and 2 mM L-glutamine (Gibco). 
The HSB-2 cell line was cultured in Iscove’s modified Dulbecco’s medium (IMDM; 
Lonza), supplemented with 10% heat-inactivated FCS, 100 IU/mL streptomycin, 100 
IU/ml penicillin, and 2 mM L-glutamine.
To obtain CD14+  monocytes, PBMCs were freshly isolated from the blood of 
healthy volunteers by density gradient centrifugation using Ficoll-Paque™ PLUS 
(GE Healthcare). Monocytes where enriched from the PBMC fraction by magnetic 
separation with CD14 magnetic beads (MACS; Miltenyi Biotec).
Flow cytometry
CCR5 expression on Jurkat, HSB-2, Molt-4 and primary T cells was determined 
by flow cytometry, using the mouse monoclonal antibody MC-5 (kind gift of Prof. 
M. Mack, University of Regensburg, Regensburg, Germany) and a PE-conjugated 
anti-mouse IgG secondary antibody (Becton Dickinson) and the appropriate con-
trols. Data acquisition was performed on a FACSCalibur flow cytometer (Becton 
Dickinson) using Cell Quest programming. Data was analyzed using the FlowJo 
software package.
Bisulphite sequencing
Total genomic DNA was isolated from naïve and activated T cells, Jurkat T leu-
kemia cells, and CD14+ monocytes. One µg of genomic DNA was used to bisulphite 
convert unmethylated CpGs using the EZ DNA Methylation kit (Zymo Research). 
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CCR5 promoter DNA was then amplified using primer sets for specific CpG contain-
ing regions (Table 4–1, Figure 4–2). PCR products were purified using the NucleoSpin 
Extract II kit (Macherey-Nagel), cloned into pGEM-T easy vector (Promega), and in-
dividual clones were sequenced at the Leiden Genome Technology Center. Results 
of at least 10 individual clones are represented as pie charts for each CpG analyzed. 
The percentage of methylated clones is depicted in black.
Table 4–1:  Primers used for ChIP, bisulphite sequencing and qPCR.
Gene Promoter region
Region spanning, 
relative to CDS Primer sequence, 5’-3’ Application
CCR5




B3 -2625 to -2434a
F: TTTAGAAAAAGATGGGAAATTTGTT
R: TCCTAAACTTCACATTAACCCTATATC
















+276 to +609 
(isoform a)d









a: Based on accession number NC_000003.10 
b: Based on accession number NM_000579.3 
c: Based on accession number NM_000937.2 
d: Based on accession number NM_004379.3 
e: Based on accession number NM_134442.3 
f: Based on accession number NM_182717.1
Chromatin immunoprecipitation (ChIP)
ChIP was performed as described earlier.26 One µg of cross-linked DNA was im-
munoprecipitated with antibodies (5 µg) directed to specific histone modifications 
(Table 4–2), or no antibody as background control. Quantitative PCR (qPCR) of the 













CREB-1 Rockland 100-401-195; [62]
RNA pol II Santa Cruz sc899x
Zebularine, DZNep and MS275 treatment
For induction of expression of CCR5, Jurkat, HSB-2 and Molt-4 cells were ex-
posed to 100 μM of Zebularine (V.E. Marquez) for 96 hours followed by an additional 
treatment with 2 μM of 3-Deazaneplanocin A (DZNep, V.E. Marquez) for 72 hours 
and 0.5 μM MS275 (Sigma-Aldrich) for 48 hours in IMDM (HSB-2) or RPMI-1640 
(Jurkat and Molt-4) with supplements as described above.
RNA isolation and (quantitative) RT-PCR
Total RNA was isolated using the RNA-Bee extraction method (TelTest) from 
naïve and activated CD4+ T cells, from CD14+ monocytes and from Jurkat, HSB-2 
and Molt-4 cells prior to and after treatment with Zebularine, DZNep and MS275. 
From 1µg of RNA, cDNA was synthesized using 250ng random hexamers (Promega) 
and Superscript III reverse transcriptase (Invitrogen).
CCR5 and RNA polymerase II (RPII) transcripts were quantified on an iCycler 
IQ system (BioRad Laboratories) using the IQ SYBR Green Supermix (BioRad 
Laboratories). Relative transcript levels of CCR5 were calculated with the compar-
ative Ct method (or ΔΔCt method) and related to RPII transcript levels. The induced 
levels of CCR5, after treatment of Jurkat, Molt-4 and HSB-2 cells with Zebularine, 
DZNep and MS275, are also depicted relative to the CCR5 expression level in in vitro 
activated primary T cells. The primers used in the qPCR reactions are shown in 
table 4–1.
CREB‑1 and inducible cAMP early repressor (ICER), the inducible isoform of 
cAMP‑responsive element modulator (CREM) transcripts were analyzed in triplicate 
by semi-quantitative PCR as previously described.26 PCR products were separated 
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by gel electrophoresis on a 1.5% agarose gel, run at 90V for 45min, and visualized by 
ethidium bromide staining. Densitrometric analysis was performed in ImageJ (U.S. 
National Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/).
Results
DNA methylation patterns of the CCR5 P1 promoter.
Using flow cytometry we found that only a few naïve primary CD4+ T  lympho-
cytes express low levels of CCR5 at the cell surface, whereas CCR5 cell surface 
expression is markedly upregulated after in vitro activation of these cells (Figure 
4–1A). The CCR5 cell surface expression pattern of activated CD4+ T cells is accom-















































Figure 4–1.  (A) Cell surface expression of CCR5 in Jurkat T leukaemia cells, naïve and activated 
CD4+ T cells as determined by flow cytometry. Numbers indicate percentage of CCR5 
positive cells. (B) Relative transcript levels of CCR5 in various cells types. Numbers 
indicate expression percentage relative to RNA polymerase II (RPII). N.D. indicates 
transcript levels were below the detection threshold.
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CCR5 transcripts were detected at low levels (Figure 4–1B). Myeloid cells, such as 
monocytes express CCR5 at low to intermediate levels.39 When compared with ac-
tivated and naïve CD4+ T cells, CD14+ monocytes indeed show intermediate levels 
of CCR5 transcripts (Figure 4–1B). In contrast, most established tumour T cell lines 
completely lack CCR5 surface expression, including the human CD4+ leukemic 
T cell lines Jurkat, Molt-4 and HSB-2 (Figure 4–1A and Figure 4–5A). Furthermore, 
these leukemic T  cell lines show only very low or undetectable CCR5 transcript 
levels (Figure 4–1B).
Evaluating the role of epigenetic mechanisms in the regulation of CCR5 expres-
sion we first assessed the CpG methylation status of three subregions regions of 
the CCR5 downstream promoter P1 (Figure 4–2). The most downstream subregion 
(B4/5), which is known to be transactivated by CREB-1,26 appears to be mostly un-
methylated and displays only marginal differences in DNA methylation between 
the various cell types (Figure 4–2). The upstream subregions B1 and B3 display 
remarkable differences in DNA methylation status. In activated T cells, the CpG 
residues in these subregions of the P1 promoter display low levels of DNA methy-
lation. In monocytes, which express intermediate levels of CCR5, the promoter 
subregions B1 and B3 are highly methylated, while the B4/5 region displays low 
levels of DNA methylation (Figure 4–2). By contrast, in naïve CD4+ T cells these sub-
regions are mainly methylated and almost completely methylated in Jurkat T cells. 
Together, these data reveal that the intermediate, low and lack of CCR5 transcrip-















Figure 4–2.  Methylation analysis of the CCR5 promoter of several cell types. Each circle 
represents a single CpG residue. The percentage of clones methylated at a specific 
residue is indicated by the black colour. The distance between each circle represents 
the relative distance between CpG residues on the genomic sequence. Horizontal 
arrows indicate the relative position of primers used to amplify bisulphite modified 
DNA. The CREB-1 binding site most likely involved in CCR5 transactivation is indicated 
with a vertical arrow.26 Other transcription factors that have been attributed to CCR5 
transcription regulation are indicated with grey arrows. The region investigated by 
chromatin immunoprecipitation is annotated as “ChIP region”.
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respectively, are associated with high levels of DNA methylation in the subregions 
B1 and B3 of the P1 promoter but not in the B4/5 subregion.
Histone modifications of the CCR5 P1 promoter
Next we determined the association of specific histone acetylation and methy-
lation modifications within chromatin of the CCR5 P1 promoter by chromatin 
immunoprecipitation (ChIP) (Figure 4–2 and Figure 4–3A–C). CCR5 expressing, ac-
tivated, CD4+ T cells display relative high levels of H3Ac (Figure 4–3A). Interestingly, 
monocytes display H3Ac levels in chromatin of the CCR5 P1 promoter, which are 
similar to activated T cells (Figure 4–3A). This is in contrast to the non-CCR5 ex-
pressing naïve T cells and Jurkat T cells, which display markedly lower levels of 
H3Ac in CCR5 P1 chromatin.
CCR5-expressing activated T cells display relatively high levels of the permis-
sive 3MeK4H3 mark in CCR5 P1 chromatin. Interestingly, naïve T cells expressing 
low levels of CCR5 show similar levels of the permissive 3MeK4H3 mark (Figure 
4–3A). In contrast, CCR5-deficient Jurkat T cells display low levels of the permis-
sive 3MeK4H3 modification (Figure 4–3A).
The repressive marks H3K9Me3 and H3K27Me3 are only present at very low 
levels in chromatin of low CCR5-expressing naïve T cells (Figure 4–3B). In contrast, 































































Figure 4–3.  Chromatin environment at the CCR5 promoter as determined by ChIP analysis. CCR5 
expressing activated CD4+  T  cells clearly show higher levels of transcriptionally 
permissive chromatin marks H3Ac and H3K4Me3 (A) whereas there is an opposite 
association with transcriptionally repressive chromatin marks H3K9Me3, H3K27Me3 
(B) and H4K20Me3 (C). These non-permissive marks are clearly present in higher 
amounts in CCR5 non-expressing cells (Jurkat T leukaemia cells, naïve CD4+ T cells) 
versus expressing activated CD4+ T cells. Naïve T cells and CD14+ monocytes show 
a poised chromatin state, encompassed by both transcriptionally permissive and 
non-permissive marks. Whereas naïve T  cells show relatively low levels of H3Ac, 
monocytes have high levels of H3Ac.
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of naïve T cells (Figure 4–3C). The presence of both an activating mark (3MeK4H3) 
and a repressive mark (H4K20Me3) indicates a bivalent, so-called ‘poised’ state of 
the CCR5 promoter chromatin of naïve CD4+ T cells.
Activated CD4+ T cells show a twofold higher CCR5 transcription level as com-
pared to monocytes. Assessing the chromatin status of CD14+ monocytes, we 
observe the presence of relative high levels of the repressive marks H3K9Me3 
and H3K27Me3 in the monocytic CCR5 P1 promoter (Figure 4–3B). Conversely, 
the repressive mark H4K20Me3 is only slightly enriched in monocytes as com-
pared to activated T cells (Figure 4–3C). Furthermore, hardly any of the permissive 
3MeK4H3 mark could be detected, yet monocytes show high levels of H3Ac in the 
CCR5 promoter (Figure 4–3A). This indicates that also monocytes display a chroma-
tin state in which repressive and permissive histone modification marks co-exist. 
Compared to naïve CD4+ T cells however the chromatin state of CD14+ monocytes, 
is markedly different, permitting transcription of CCR5.
CCR5-deficient Jurkat T  cells show relative high levels of the repressive 
H3K9Me3 and H3K27Me3 histone marks, when compared with naïve and activated 
T cells (Figure 4–3B). Like naïve T cells, Jurkat T  leukemia cells also show high-
er levels of the repressive H4K20Me3 modification when compared to activated 
T cells (Figure 4–3C). The presence of these repressive marks in the absence of ac-
tivating histone modifications clearly shows a repressive chromatin conformation 
encompassing the CCR5 P1 promoter in Jurkat T cells.
Taken together, these data show that there is a differential pattern of chromatin 
conformation of the CCR5 P1 promoter region in the different cell populations in-
vestigated in this study. Our observations also indicate that the CCR5 transcription 
profiles could not be explained by a single epigenetic modification, but rather the 
sum of modifications appears to determine the level of CCR5 transcripts in the var-
ious cell types investigated.
Re-expression of CCR5 through pharmacologic interference in epigene-
tic mechanisms in Jurkat, Molt-4 and HSB-2 T cell lines
To show that DNA methylation, and histone acetylation/methylation mechanisms 
control CCR5 transcription, we aimed to induce CCR5 transcription in non–CCR5-
expressing cells through pharmacologic interference in the catalytic activities of 
the various enzymes involved in these epigenetic regulatory processes. Figure 4–4 
presents a schematic overview of the working mechanisms of the agents used for 
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this purpose. Zebularine is a potent inhibitor of DNA-methylation showing much 
lower toxicity then the widely used inhibitor 5-Aza-dC.40,41 First recognized as an 
inhibitor with specificity for the KMTase EZH2, DZNep is now regarded as a more 
general lysine methyltransferase inhibitor, with a high affinity for the enzymes that 
triple-methylate K20H4 and K27H3 (Miranda et al. (2009),42 Tan et al. (2007)43 and 
own observations). Finally, MS275 is a potent inhibitor of histone deacetylase activ-
ities (HDACs), with high affinity for the class I HDACs 1 and 3.44
Originally we found that inhibition of DNA-methylation by 5-Aza-dC treatment 
resulted in only a modest and time-dependent induction of CCR5 mRNA expression 
levels in Jurkat cells (results not shown). However, combining inhibition of DNA and 
histone methylation by inclusion of DZNep resulted in a clear synergistic induction 
of CCR5 mRNA expression, whereas inhibition of histone methylation alone was 
found only marginally effective (results not shown). Additional treatment with the 
HDAC inhibitor MS275 mainly potentiated the effect obtained by the other inhibitors 
(results not shown).
We therefore combined all of the above-mentioned inhibitors to induce CCR5 
expression in Jurkat, Molt-4 and HSB-2 T leukemia cells and included Zebularine 
rather than 5-Aza-dC for the aforementioned reasons. After treatment with 














Figure 4–4.  Schematic representation of the working mechanism for the pharmacological 
intervention in CCR5 transcription. Zebularine inhibits DNMTs, whereas MS275 
inhibits HDACs. DZNep is a more general KMTase inhibitor.42
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positive as determined by flow cytometry (Figure 4–5A). In untreated Jurkat cells, 
only 0.83% of the cells stain positive for CCR5 (Figure 4–1A). Correspondingly, after 
treatment the levels of CCR5 transcripts found in Jurkat T cells increased to 43% 
of the CCR5 transcript levels found in activated CD4+ T cells (Figure 4–5B). HSB-2 
and Molt-4 were more refractory to this combined epigenetic treatment, however 
still 49.4% and 18.2% of the cells respectively were expressing CCR5 at the cell 
surface after treatment (Figure 4–5A), whereas transcript levels were 20% and 
4.8% relative to activated T cell transcript levels in HSB-2 and Molt-4 respectively 
(Figure 4–5B).
Next we evaluated the effect of the epigenetic drug treatment on the expression 
characteristics of CREB-1 and ICER in Jurkat cells by semi-quantitative RT-PCR 
as we have previously explored.26 ICER, the inducible cAMP early repressor, which 
is induced by forskolin, competes with CREB-1 for DNA binding. We and more re-
cently also others have shown that induction of ICER by forskolin treatment indeed 
reduces CCR5 expression.26,45 In figure 4–6 it is shown that pharmalogical induction 















































Figure 4–5.  (A) Restoration of CCR5 expression in Jurkat, HSB-2 and Molt- 4 T  leukaemia cell 
lines following exposure of cells to Zebularine, DZNep and MS275 determined by flow 
cytometry. Numbers indicate the percentage of CCR5 positive cells; filled histograms 
represent the non-treated cells and open histograms the treated cells. (B) Levels of 
CCR5 transcripts in treated Jurkat, HSB-2 and Molt-4 T  leukaemia cells relative to 
CCR5 transcript levels in activated CD4+ T cells. The transcript level data of activated 
T cells are the same as shown in figure 4–1B.
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of ICER in Jurkat T  cells. Notably, when compared with naïve or activated CD4+ 
T cells, Jurkat cells do express CREB-1, but hardly any ICER could be detected. In 
contrast, naïve T cells show low levels of CREB-1, with relatively high levels of ICER. 
Upon activation, the levels of ICER are reduced while on the other hand CREB-1 
levels are induced (Figure 4–6). These observations indicate that in Jurkat T cells 
induction of CCR5 expression most likely is not resulting from alterations in the 
interplay of CREB-1 and ICER.
We also investigated whether the pharmalogical induction of CCR5 expression 
was associated with alterations in the histone acetylation/methylation profile and 
recruitment of CREB-1 and RNA polymerase II in CCR5 promoter chromatin. As 
shown in figure 4–7A there is a clear increase in the H3Ac mark (associated with 
gene expression) after treatment, whereas histone marks associated with gene re-
pression appear to be more resistant to the treatment. Shown in figure 4–7B is that 
the permissive CCR5 chromatin structure in activated T cells (Figure 4–3) results 
in increased recruitment of CREB-1 and RNA polymerase II into CCR5 promot-
er chromatin when compared with naïve T cells. Similarly, the induction of CCR5 


























Figure 4–6.  Semi-quantitative RT-PCR for CREB-1 isoforms and ICER were performed in triplicate. 
Activated T  cells show higher levels of both CREB-1 isoforms, when compared to 
naïve T cells, whereas naïve T cells show higher levels of ICER then activated T cells. 
Jurkat T  leukaemia cells show virtually undetectable levels of ICER. Treatment of 




increase in the recruitment of CREB-1 and RNA polymerase II into CCR5 promoter 
chromatin (Figure 4–7B). Together, the pharmalogical inhibition of the activities of 
the various epigenetic enzymes that account for the repressive chromatin state of 


















































































Figure 4–7.  (A) ChIP analysis of histone modification at the CCR5 promoter in Jurkat cells, after 
treatment with Zebularine, DZNep and MS275. The treatment of Jurkat cells results 
in an increase of H3Ac at the CCR5 promoter. Repressive marks at the CCR5 chromatin 
are not influenced much by the treatment, although a minor decrease in H3K27Me3 
can be noted. (B) ChIP analysis of the CCR5 promoter for CREB-1 and RNA polymerase 
II after treatment with SMIs in Jurkat, compared to both naïve and activated T cells. 
Treatment of Jurkat cells with Zebularine, DZNep and MS275 slightly increases CREB-
1 in chromatin of the CCR5 promoter. In both naïve and activated T cells higher levels 
of chromatin-associated CREB-1 can be found. Compared to naïve T  cells, there 
is an increase of CREB-1 in activated T  cells. Treatment of Jurkat cells with SMIs 
increases RNA polymerase II recruitment to the CCR5 promoter to levels similar of 
naïve T cells. In comparison to activated T cells, the levels of RNA polymerase II in the 
CCR5 promoter region of treated Jurkat cells are modest.
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This is accompanied by an increase in promoter association of the transcription 
factor CREB-1 and recruitment of RNA polymerase II.
Discussion
This study reveals that epigenetic mechanisms involving DNA methylation, his-
tone acetylation and methylation modifications all contribute to the transcriptional 
regulation of CCR5 expression. In CCR5-deficient T  leukemia cells we show that 
the promoter region is mainly characterized by repressive histone marks in the 
presence of methylated DNA. In CCR5-expressing activated T cells this region is 
mainly associated with activating histone marks and low levels of DNA methylation. 
Interestingly, the B4/5 region in the CCR5 promoter, which was previously attribut-
ed to CREB–1-mediated transactivation is mostly unmethylated both in Jurkat and 
activated T cells.
Intermediate or low CCR5-expressing monocytes and naïve T cells respectively 
are characterized by both repressive histone methylation marks and permissive 
histone acetylation marks. In naïve T cells an intermediate level of DNA methyla-
tion accompanies these histone modifications. However, in monocytes the level of 
DNA methylation is markedly higher as compared to naïve T cells, with the B4/5 
region in a mostly unmethylated state in both cell types. Together, the cell types 
investigated here show that the B4/5 region is mostly unmethylated, irrespective of 
CCR5 transcription. This suggests that the B1 and B3 regions could contribute to 
the transcriptional regulation of CCR5 as has been argued previously.26,46,47
Notably, monocytes and naïve CD4+ T cells represent a poised state recognized 
by the presence of both repressive and permissive histone marks. Considering the 
various histone triple-methylation modifications investigated, we conclude that 
acetylation of histone H3 is essential for CCR5 expression as is illustrated in naïve 
T cells and in monocytes. The dominant role of histone modifications is further un-
derscored by the fact that monocytes show high levels of DNA methylation. Although 
DNA methylation is usually interpreted as a repressive chromatin mark, this study 
as well as some recent other studies show that DNA methylation in the absence 
of repressive histone marks permits active gene transcription.48–54 This is also in 
line with previous studies showing that the presence of the H3K27Me3 histone 
modification correlated with lack of transcription despite absence of DNA methy-
lation.50,55,56 Interestingly, the monocyte population presented in this study shows 
transcription in presence of DNA methylation, H3K27Me3, H3K9Me3 and H3Ac, 
but notably low levels of H4K20Me3. This underscores – as has been previously 
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noted48 – that not all epigenetic histone marks contribute equally to a specific chro-
matin status. Rather, the sum of epigenetic modifications, or “epigenetic profile”, is 
more important than individual modifications to allow gene transcription.
The role of epigenetic regulatory mechanisms in the control of CCR5 tran-
scription is also underscored by the pharmacological interference in the identified 
components of epigenetic regulation. Since the epigenetic modifications were 
observed in both DNA and in histones encompassing the CCR5 promoter, we com-
bined the various inhibitors to induce re-expression. This intervention resulted in 
the re-expression of CCR5 in Jurkat, HSB-2 and Molt-4 T leukemia cells, albeit that 
the levels of re-expression differ between the cell lines investigated and were never 
on par with activated T cells. Although the individual epigenetic inhibitors allowed 
marginal induction of CCR5 transcripts (data not shown), combination of inhibitors 
induced much higher transcription levels.
Changing the DNA methylation status through pharmacological disruption with 
Zebularine requires incorporation of Zebularine into the DNA.40,41 Demethylation 
through usage of Zebularine thus requires replication of DNA and therefore prolif-
eration of cells. Jurkat, HSB-2 and Molt-4 cell lines show different doubling times. 
The difference in re-expression levels of CCR5 after combined epigenetic therapy 
can therefore be explained by this difference in cell doubling times. Furthermore 
the relative toxicity of MS275 and DZNep may lower the proliferative capacity of 
the cells, thereby influencing the efficacy of Zebularine treatment. Especially since 
DNA methylation and histone modifications are intimately linked,32,57 this may re-
sult in a situation where 100% re-expression of the gene of interest might prove 
to be a challenge. Yet despite these drawbacks, interference in the epigenetic ma-
chinery still results in a dramatic rise of CCR5 transcripts in T leukemia cells.
Together, these data strongly indicate that histone acetylation and methylation 
modification mechanisms contribute to the transcriptional control of CCR5. In 
addition, we show that chromatin in a bivalent state allows for the fine-tuning of 
transcription levels, as has been shown before for other genes.32,58 Moreover, our 
data suggest that epigenetic deregulation could be one of the mechanisms leading 
to enhanced CCR5 expression as observed in a variety of inflammatory condi-
tions. Although we demonstrate in this study the re-expression of CCR5, it could 
be envisioned that the use of lysine acetyltransferase inhibitors (e.g. curcumin or 
garcinol59,60) may have the opposite effect. As such, CCR5-mediated trafficking of 
lymphoid and myeloid cells is a possible target for pharmacological intervention. 
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Interference in these deregulated epigenetic processes may therefore be a prom-
ising therapy for the treatment of inflammatory diseases.
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Recently we described that the C-allele of a polymorphism (rs2948080) located 
2481bp upstream of the transcription start-site of the KAT P300/CBP-associated 
factor (PCAF, or KAT2B) is associated with a significant reduction in vascu-
lar morbidity and mortality. Given the localization of this polymorphism in the 
PCAF promoter, we have investigated whether this polymorphism has an im-
pact on the constitutive transcript levels of PCAF. We therefore analysed PCAF 
transcription levels in two cell types relevant for human vascular disease: 
monocytes and Human Umbilical Cord Endothelial Cells (HUVECs). No sig-
nificant differences were observed in constitutive PCAF transcript levels with 
regards to the genotype of either the monocytes or HUVECs in this cohort of in-
vestigated individuals. Therefore, the exact mechanism by which the –2481G/C 




Epigenetic processes hereditably influence gene expression without modifying 
the actual genetic code. It is commonly thought to provide an essential linkage 
between environmental factors and gene expression. Given the impact of envi-
ronmental factors on atherosclerosis, in recent years the field of epigenetics is 
intensively investigated and evidence for epigenetic contribution to diseases is 
slowly accumulating.1,2 Epigenetics is commonly thought to provide an essential 
linkage between environmental factors and gene expression.3 In recent years, 
many advances have been made in the field of epigenetics and evidence for epige-
netic contribution to diseases is slowly accumulating.1
A myriad of cellular processes (e.g. DNA methylation and histone modifica-
tions) are responsible for epigenetic regulation. Post-translational modifications of 
N-terminal tails of histone proteins are key-components in the epigenetic regulation 
of genes. Over 60 distinct modifications are currently known – mostly in the histone 
tails – although some have been observed in the globular domain.4,5 Modifications 
of histone tails include (amongst others) acetylation and methylation of lysine res-
idues. Whereas acetylation of histone tails is correlated with gene activation,6–8 the 
influence of histone methylation depends on the exact residue methylated and the 
number of added methyl groups.9–11 Post-translational modifications made to the 
histone-tails are reversible. Acetylation at lysine residues in the histone N-terminal 
tails is established by lysine acetyltransferases (KATs). KATs are counteracted by 
histone deacetylases (HDACs) and Sirtuins (SIRT). Likewise, histone methylations 
established by lysine methyltransferases (KMTs), can be counteracted by lysine 
demethylases (KDMs). In this way these enzymes promote a return to respectively 
repressive or active chromatin structure.12–14
Recently we described that the C-allele of a polymorphism (rs2948080) located 
2481bp upstream of the transcription start-site of the KAT P300/CBP-associated 
factor (PCAF, or KAT2B) is associated with a significant reduction in vascular mor-
bidity and mortality.15 Besides that the –2481 SNP was associated with survival, 
PCAF transcription levels were significantly altered in a mouse model of reactive 
stenosis, providing an indication that PCAF in involved in vascular remodelling. In 
an electrophoretic mobility shift assay, we found differential protein binding to the 
different alleles. This study underscored the concept that epigenetic processes are 
also under genetic control. Given the localization of this polymorphism in the PCAF 
promoter, we have investigated whether this polymorphism has an impact on the 
constitutive transcript levels of PCAF. We therefore analysed PCAF transcription 
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levels in two cell types relevant for human vascular disease: monocytes and 
Human Umbilical Cord Endothelial Cells (HUVECs).
Materials and Methods
Study subjects
Per genotype 5 patients were selected from the GENDER study population. 
This study has been described previously.16 In brief, the GENetic DEterminants of 
Restenosis project (GENDER) was a multicenter follow-up study designed to study 
the association between various gene polymorphisms and clinical restenosis. 
Patients eligible for inclusion in the GENDER study were treated successfully for 
stable angina, non-ST–elevation acute coronary syndromes or silent ischemia by 
PCI in 4 out of 13 referral centres for interventional cardiology in The Netherlands. 
Patients treated for acute ST-elevation myocardial infarction were excluded. 
Written informed consent was obtained from all participants. The study protocol 
conforms to the Declaration of Helsinki and was approved by the ethics committees 
of each participating institution.
Cell isolation and culturing
Blood was drawn into citrate tubes (Greiner) and PBMCs where isolated by den-
sity gradient centrifugation using Ficoll Isopaque plus (GE healthcare). Five parts 
of blood where diluted with one part of buffer consisting of PBS (LUMC Pharmacy) 
+ 10% v/v GPO (Sanquin) + 10% v/v Sodium Citrate (LUMC Pharmacy). PBMC frac-
tion was recovered and washed tree times in buffer. Monocytes where isolated 
from the PBMC fraction by magnetic separation with CD14 magnetic beads (MACS; 
Milteny Biotech).
HUVECs from 10 umbilical cords, were isolated following established proto-
cols,17 and cultured until confluence in EGM-2 medium (Lonza) in T75 culture flasks 
coated for 30 min at 37°C in 5% CO2, with 1% w/v gelatine. Cells were harvested 
using a cell scraper and washed two times in cold PBS then RNA and genomic DNA 
(gDNA) was extracted (see page 121). Following gDNA extraction, the genotype 
of the HUVECs was assessed using Sanger sequencing (performed by the Leiden 




Table 5–1:  Primers used for qPCR and sequencing analysis.











The cell lines used for the preparation of nuclear extracts were obtained through 
the ATCC and were cultured in Iscove’s modified Dulbecco’s medium (IMDM; 
BioWhittaker Europe, Verviers, Belgium) supplemented with 10% (v/v) heat-in-
activated foetal calf serum (FCS; Greiner, Alphen a/d Rijn, The Netherlands), 100 
IU/ml streptomycin and 100 IU/ml penicillin. For interferon-γ (IFN-γ) inductions, 
cells were treated with 500U/ml of IFN-γ (Boehringer-Ingelheim, Alkmaar, The 
Netherlands) for 4 hours; hereafter nuclear extracts were prepared (see below).
For the preparation of nuclear extracts HUVECs were isolated as described 
on page 119 and cultured in Medium 199 with Earl’s Salt and L-glutamine (Life 
Technologies, Breda, The Netherlands), supplemented with 20% (v/v) FCS (PAA, 
Pasching, Austria), 100 IU/ml streptomycin and 100 IU/ml penicillin, 10 IU/ml hep-
arin (Leo Pharma, Breda, The Netherlands) and 25 mg Bovine Pituitary Extract 
(BPE; Life Technologies, Breda, The Netherlands).
For IFN-γ inductions of HUVECs, cells were treated with 500 U/ml of IFN-γ 
(Boehringer-Ingelheim, Alkmaar, The Netherlands) for 4 hours; hereafter nuclear 
extracts were prepared (see below).
Transcription factor binding site search
Potential transcription factor binding sites were identified using the TFSEARCH 
program (http://www.cbrc.jp/research/db/TFSEARCH.html), which searches the 
TRANSFAC database.18,19 Cut-off was set at 75% of the consensus TF binding site.
Nuclear extracts and electrophoretic mobility shift assay (EMSA)
Nuclear extracts and EMSAs were performed as described previously.20 
In brief, 2 µl of nuclear extracts in binding buffer were incubated for 30 min-
utes on ice, with 2 ng of a [33P]-labelled double stranded DNA probe. The probe 
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sequences were similar to either the C or G promoter variants of the PCAF-
gene (PCAF-C: 5’–GCAATAAGCCTCCTCAATCCTTTGCCCTTG–3’; PCAF-G: 
5’–GCAATAAGCCTCCTGAATCCTTTGCCCTTG–3’). Probe sequences for tran-
scription factors MZF1 and GATA1-3 were similar to their previously described 
consensus sequence (MZF1 (zinc fingers 1–4): 5’–GATCTAAAAGTGGGGAGAAAA–3’; 
MZF1 (zinc fingers 5–13): 5’–GATCCGGCTGGTGAGGGGGAATCG–3’; GATA: 
5’–GGACCTTGATCTTATCTT–3’).21,22
In the case of competition assays, nuclear extracts were incubated with unla-
belled oligonucleotides in 100-fold excess for 30 min on ice, prior to incubation with 
the labelled probe. In case of interferon-γ treated samples, cells were stimulated 
with interferon-γ (500U/ml; Boehringer-Ingelheim, Alkmaar, The Netherlands) for 
24-hours prior to preparing nuclear extracts. Samples were run on a 6% poly-
acrylamide gel in 0.25x TBE-buffer for 2 hours at 200 V. Gels were densitometrically 
analysed using the ImageJ software.23
RNA/DNA isolation and cDNA synthesis
From 1 × 106 CD14+ monocytes total RNA was isolated. After harvesting HUVECs, 
half of the cells were used for RNA isolation and the other half was used for genom-
ic DNA (gDNA) isolation. Cells were centrifuged for 5 min at 500 × g and lysed in 
RNAbee according to manufacturer’s instructions. Lysates were stored at -80°C 
until further processing. Total RNA was then extracted according to manufactur-
er’s instructions. Subsequently from 1 µg total RNA, cDNA was synthesized using 
SuperScript III (Invitrogen), with random hexamers (Promega), at 50°C for 1 hour 
according to manufacturer’s instructions. Genomic DNA was extracted by stand-
ard chloroform/phenol extraction.24
qPCR
Quantitative PCR was performed on a Bio-Rad iCycler 5 with SYBR Green su-
permix (Bio-Rad) For each reaction, 125 ng of cDNA and 5 pmol of forward and 
reverse primer (Table 5–1) were used in a total volume of 25µL. Transcription levels 
were normalized against RNA Polymerase II (RPII). Both primer-pairs produce a 
single amplicon. Amplicons were sequenced to confirm the identity of the target 
sequence. The PCR-program used was: 95°C for 3 min, followed by 40 cycles [30 
sec 95°C; 30 sec 60°C; 30 sec 72°C] and was concluded by melting curve analysis 




Data was analysed using an ANOVA and corrected for multiple testing using the 
Bonferroni method with the in SPSS software package (version 17). Data was con-
sidered significant when p < 0.05 after multiple testing correction.
Results
In a previous study, the –2481 polymorphism was correlated to decreased vas-
cular morbidity and mortality.15 Using the EMSA technique we tested whether the 
observed polymorphism would lead to differential protein binding in vitro. Using 
nuclear extracts of different cell types, we studied complex formation at the –2481 
region of PCAF. We could detect constitutive protein binding to both PCAF C and 
G-variants (Figure 5–1A). In both HUVEC and U251 cells nuclear factor binding is 
slightly enhanced by IFN-γ stimulation. Densitometric analysis revealed that the 
PCAF G-variant exhibits slightly stronger protein binding in some cell types than the 
C-variant, although these differences are not statistically significant. Competition 
assays also suggest a modest difference in binding affinity (Figure 5–1B).
Using the TFSearch program,19 we identified possible binding sites for MZF1 and 
GATA1-3 in the PCAF C-variant promoter. However, ds-oligonucleotides represent-
ing the consensus binding sites for MZF1 and GATA1-3 did not compete with factor 
binding to the PCAF C promoter variant (data not shown).
Probe
IFN-γ
G CG C G C G C G C G C G C
+ – + + ––













Figure 5–1.  Protein binding to the C and G-variant of the –2481 region. (A) Electrophoretic 
mobility shift assays (EMSA) showing binding of protein to the C and G-variant of the 
–2481 region using nuclear extracts of various cell-lines. EMSA suggests slightly 
stronger binding of protein to the G-variant of the –2481 region, most pronounced 
in human umbilical vein endothelial cells (HUVEC) and U251 cells. (B) Competition 
assay with nuclear extracts from HeLa cells stimulated with IFN-γ also suggests 
slightly increased binding affinity for the –2481G-variant at high concentrations. 
The difference is best observed when unlabelled probe is added in 200-fold excess, 
indicating that the observed difference in affinity is weak. Shown are representatives 
of multiple independent experiments. From: Pons, D. et al. Heart (2011); 97, 143–50. 
doi:10.1136/hrt.2010.199927
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Mouse models of reactive stenosis showed that PCAF transcription was mod-
ulated after placing a non-restrictive cuff around the femoral artery.15 Given the 
location of this polymorphism in the PCAF promoter we have investigated wheth-
er this polymorphism has an impact on the constitutive transcript levels of PCAF. 
We therefore analysed PCAF transcription levels in two cell types relevant for hu-
man vascular disease: monocytes and Human Umbilical Cord Endothelial Cells 
(HUVECs). Monocytes were obtained from the previously investigated GENDER 
population. For each genotype 5 patients were randomly selected. Monocytes were 
freshly isolated from peripheral blood and total RNA was extracted directly after 
isolation. After cDNA synthesis, PCAF transcription levels were then determined 
by qPCR and normalized to transcript levels of RNA Polymerase II (RPII). The nor-
malized PCAF transcript levels in monocytes are shown in figure 5–2. No significant 
differences (p < 0.05) could be observed in PCAF transcript levels with regards to 
the genotype of the monocytes in this cohort of investigated patients.
In addition to monocytes, PCAF transcription levels were also studied in HUVECs 
from 10 umbilical cords. HUVECS were isolated as previously described by Jaffe et 
al.17 After isolation cells were grown 
to confluence and subsequently gDNA 
and RNA was isolated. PCAF transcript 
levels were determined and subse-
quently the genotype was determined 
using Sanger sequencing. The rel-
ative transcription levels of PCAF in 
HUVECS are shown in figure 5–3. Only 
C/G and G/G genotypes were found in 
the isolated HUVECs. Also in HUVECs 
no differences were found in PCAF 
transcript levels between the various 
genotypes.
Discussion
Single Nucleotide Polymorphisms 
(SNPs) in promoter regions, al-
though associated with some disease 
or mortality, can prove to be hard to 

























Figure 5–2.  Boxplot of transcription levels 
of PCAF for various genotypes 
of the –2481C/G polymorphism 
in peripheral blood monocytes. 
Transcript levels are normalized to 
RPII transcription level. Numbers 
are shown as 2log relative 
expression. Values between 
> 1.5 × IQR (inter quartile range) and 
< 3 × IQR are marked by an asterisk 




Although risk genes for various diseas-
es have been found in Genome-Wide 
Association Studies (GWAS), many of 
these failed to link functional impli-
cations to the reported risk gene.25,26 
When the –2481G/C polymorphism 
upstream of the epigenetic modifying 
enzyme PCAF was identified in a GWAS 
as a cardiovascular disease risk factor, 
we performed some initial experiments 
to find biological implications of this 
SNP.15 Through the use of an electro-
phoretic mobility shift assay, we could 
demonstrate protein binding to an ol-
igonucleotide encompassing the SNP. 
Since this protein binding showed some 
minor differential binding between the 
C/C and G/G allele, we hypothesized 
that this may result in differential PCAF 
expression.
Using quantitative PCR we measured the transcription levels of PCAF in cell 
types relevant to cardiovascular disease. Nor in monocytes, nor in HUVECs were we 
able to demonstrate a difference in PCAF transcript levels related to the –2481G/C 
polymorphism. Thus the functional implication of the SNP association to vascular 
mortality does not seem to be caused by a clear difference in basal PCAF transcrip-
tion levels. From these results it cannot be excluded though, that the –2481G/C 
polymorphism influences the regulation of PCAF expression induced by environ-
mental stimuli. Given the fact that multiple PCAF SNPs have been described and 
investigated for their association with coronary restenosis, the apparent lack of 
differences in the constitutive transcript levels of PCAF could reflect complex inter-
actions of the described genetic variations that determine the overall levels of gene 
expression. The apparent lack of correlation between a promoter polymorphism 
and transcript levels has also been observed in other genetic systems of which the 
TNF promoter polymorphisms were elaborately studied.27
The functional implication of the SNP might not necessarily be differential 
transcription of the PCAF. The SNP could also function in e.g. structural integrity 



























Figure 5–3.  Boxplot of transcription levels 
of PCAF for various genotypes of 
the –2481C/G polymorphism in 
HUVECs. Transcript levels are 
normalized to RPII transcription 
level. Numbers are shown as 
2log relative expression. No C/C 
genotypes were encountered in the 
isolated HUVECs.
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–2481G/C polymorphism could just be a proxy marker of a functional SNP located 
elsewhere.28 Since we do not observe significant differences in the levels of PCAF 
transcripts the exact mechanism by which the –2481G/C SNP protects from vascu-
lar morbidity and mortality remains to be elucidated.
Interesting to note in this respect is that the –2481G/C polymorphism was not 
reported in a systematic testing of literature reported variations associated with 
coronary restenosis.29 This systematic testing was performed on the GENDER 
study in which the –2481G/C polymorphism was originally reported.15 Although the 
authors do not report the –2481G/C polymorphism in the results, the PCAF gene is 
listed as one the top 6 most significant associated genes. This could indicate that a 
biological pathway involving PCAF or the PCAF locus is functionally involved in the 
associated survival rather than PCAF by itself.
Many GWAS have been published in the last decade and hundreds of SNPs have 
been associated with a wide variety of diseases.30 It has been argued before that 
these studies by themselves are of limited value unless in subsequent steps the 
biological relevance or pathogenic mechanisms are elucidated.30 Furthermore, the 
number of discovered variants by GWAS is strongly correlated with the experimen-
tal sample size.31 This correlation roughly predicts that after a certain sample-size 
threshold a doubling in sample-size leads to a doubling in associated SNPs.31
The data presented here illustrates that GWAS data by itself is of limited use, 
but can serve as a good starting point for further analysis. Indeed there are some 
well-studied examples were GWAS data provided a starting point for taking our 
knowledge on the mechanisms involved in the pathogenesis of certain diseases a 
step further. However this also illustrates that the real challenge in interpreting 
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Epigenetic contribution to atherosclerosis
When combining all the currently available reported data, there is evidence in 
support of the notion that epigenetic mechanisms contribute to atherosclerosis 
pathogenesis.1–3 Strong indications can be found in the fact that atherosclerosis 
pathology is characterised by many environmental risk factors.4 In some cases, 
there has been a direct link between risk factors for atherosclerosis and epige-
netic control of gene expression.5,6 Besides the risk factors contributing to disease 
development, many examples are known of the epigenetic regulation of specific 
genes involved in atherosclerosis pathology. Much of this data is summarized in 
chapter 1.
Risk factors aside, susceptibility to coronary heart disease (CHD) may (in part) 
be a consequence of events in early life. In 1992, Hales and Barker formed the 
thrifty phenotype hypothesis (also referred to as the Barker-hypothesis or foe-
tal-origins hypothesis).7 The hypothesis states that adaptation to an unfavourable 
maternal environment is beneficial to the developing embryo in utero.7,8 When en-
vironmental conditions are changed in later life, this may lead to development of 
chronic disease, such as cardiovascular disease. The observations made by Barker 
cannot be correlated to alterations in the DNA sequence, hence epigenetic regula-
tion is thought of as the underlying mechanism. This notion is strengthened by the 
altered DNA methylation patterns involving the IGF2 locus observed in the Dutch 
Hunger Winter cohort,9 but also in more controlled mouse-studies.10
Barker’s hypothesis has been much criticized. For example: it is claimed that 
Barker never properly tested his hypothesis,11 and has not corrected for confound-
ing.12,13 More importantly, the hypothesis formulated by Barker does not account 
for environmental factors and stochastic changes that occur during a lifetime. This 
‘acquired’ epigenetic contribution is indicated by e.g. the incomplete concordance 
for autoimmune diseases between genetically identical (monozygotic) twins, in 
conjunction with the finding of epigenetic drift during aging in twin cohorts.14,15 An 
alternative hypothesis, the accumulation of risk hypothesis, takes into account ge-
netic factors, the in-utero environment, and life-acquired ‘epimutations’.16 From 
monozygotic twin studies it became apparent how acquired epimutations may 
change phenotype and disease susceptibility.14,17 Importantly, when epimutations 
are acquired during a lifetime, ‘epitherapy’ might be able to reverse these epige-
netic alterations.
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Understanding of the mechanism how epigenetic gene regulation influences the 
formation of atherosclerotic plaques may help us in developing new therapies and 
prevention strategies. A comprehensive view on how our environment influences 
epigenetic regulation and how in turn this epigenetic regulation affects athero-
sclerosis development is very valuable in this respect. In the research presented in 
this thesis an attempt was made to provide an integrative approach. Starting with 
identifying epigenetic components in human atherosclerotic plaques (chapter 2) 
and then cascading down to an individual gene level (chapters 4 & 5).
Identification of epigenetic components in plaques
The clinical manifestation of atherosclerosis is present in the form of plaques 
in the arterial intima.18 Therefore, to evaluate how epigenetics is contributing to 
this disease, the epigenetic components of the plaque where examined in chapter 
2. Using immunohistochemistry, the aim was to identify aberrant epigenetic pat-
terns that could be correlated with plaque stage. Using this method a reduction of 
H3K27Me3 was found in the tunica media of late atherosclerotic plaques. Although 
a significant reduction was found, the results found is this study should be fur-
ther validated given the inherent difficulties of analysing IHC data in a quantitative 
manner.
The quantitative analysis of this study is mainly hampered by two factors. 
Firstly, staining intensity is not always correlated with protein concentration.19 
Furthermore DAB staining does not follow Lambert Beers Law, complicating 
quantification. Secondly, DAB and haematoxylin are hard to spectrally unmix by 
image processing.20 In the data presented in chapter 2, the haematoxylin staining 
is often overpowered by strong DAB intensity. Although these factors can be mostly 
overcome by choosing an immunofluorescence method over IHC, this does not im-
ply that staining intensity can be correlated with protein concentration when using 
immunofluorescence.
Besides these methodological considerations, the staining pattern of the posi-
tive control (total H3) raises some questions that should be addressed. In stainings 
directed to total H3 not every nucleus stains positive. This can potentially be ex-
plained by the fact that a limiting dilution is used on the primary antibody. However, 
this can also be explained by an accessibility artefact, either due to the origin of 
the sample (FFPE material) or by the antigen retrieval-method used. Although this 




In chapter 2, it was observed, that the reduction in in H3K27Me3 staining was 
not accompanied by a reduction in the H3K27Me3 associated proteins JMJD3, EZH2 
and BMI1. Whether the reduction of H3K27Me3 is the result of altered targeting of 
H3K27Me3 modifying enzymes, or due to reduced activity of these enzymes, re-
mains to be established. Additionally, in chapter 2, it was observed that the tunica 
adventitia shows a higher percentage of positive nuclei, regardless of the staining. 
It needs to be confirmed whether this is a reflection of cell types residing in the 
tunica adventitia.
Epigenetic components in monocyte differentiation
Even though FFPE material is available to study plaque composition, it is un-
fortunately impossible to follow the dynamic process of plaque formation in vivo. 
Neither is it possible to simulate plaque formation in vitro. As such only certain 
components of the plaque formation process can be studied.
In the tunica media reside many infiltrating cell types, including one of the main 
precursor cells to plaque formation: monocytes. As reviewed in chapter 1, mono-
cytes infiltrate the subendothelium and there differentiate into macrophages. Since 
this differentiation process is a key element in plaque formation it was extensively 
studied in chapter 3.
By using quantitative PCR the transcript levels of genes encoding for epigenet-
ic modifying enzymes were evaluated during the differentiation of monocytes into 
macrophages or dendritic cells (DCs). With the notable exception of KATs and PcG 
genes, all major classes of the genes encoding epigenetic modifying enzymes are 
differentially transcribed when comparing monocytes to either macrophages (type 
1 and type 2) or to immature dendritic cells. Further stimulation with LPS did not al-
ter these expression patterns. On a single gene level, only KMT1C was found to have 
significantly altered transcription levels during differentiation of monocytes into 
various lineages. Blocking KMT1C activity with BIX-01294 resulted in a reduction 
of DC‑SIGN transcripts, while at the same time cell surface expression of DC-SIGN 
was hardly affected. However, surface expression of DC-SIGN was reduced when 
applying the general KMTi DZNep. This reduction in surface expression of DC-SIGN 
was even more pronounced when BIX-01294 and DZNep were combined.
Previous work published on epigenetic regulation involving monocytes focuses 
mainly on the epigenetic regulation of single genes, including following the re-
sponse to interferon stimulation. For instance, histone H3-Lysine 9 methylation 
Summary & General discussion
133
has been shown to be involved in the regulation of single genes following monocyte 
differentiation.21,22 In chapter 2 a reduction in H3K27Me3 levels was identified in 
late-stage atherosclerotic plaques. This specific post-translation histone modifi-
cation has been shown before to be involved in the regulation of CD14 and CD209 
(DC‑SIGN) transcription during monocyte differentiation.23 Epigenetic modifying 
enzymes putting the H3K27Me3 mark in effect however were neither identified as 
being transcriptionally altered (chapter 3) nor did they show altered expression 
(chapter 2) during monocyte differentiation. It is likely that the epigenotype switch-
ing at the CD14 and CD209 loci is the result of differential targeting of epigenetic 
modifying enzymes without an alteration in transcript or protein expression levels.
Recently, a large advancement in understanding monocyte differentiation has 
been made by the first genome-wide epigenetic profiling of monocyte to mac-
rophage differentiation.24 However, from an epigenetic point of view, monocyte 
differentiation is not yet as well understood as T cell differentiation is. The differ-
entiation of naïve T cells into Th1 or Th2 is determined by the cytokines IL-12 and 
IL-4, respectively. In response to these signals, transcription is initiated of line-
age specific cytokine genes including IFN‑γ and IL‑4.25 The IFN‑γ and IL‑4 loci are 
maintained in a ‘poised’ state in naïve T cells—i.e. they show both repressive and 
activating epigenetic marks—allowing rapid, early transcription. Such a poised 
state resembles the multivalent states observed for CCR5, as described in chapter 
4. The multivalent state for CCR5 however is used for fine-tuning of transcription 
levels instead of rapid transcription upon induction. It has been suggested that 
conclusions made from studies of T cells are broadly relevant to differentiation in 
other cell types and tissues.26 In particular, the concepts of transcriptional poising 
and promoter bivalency as mechanisms that regulate fate decisions are pertinent 
during the differentiation of stem cells and less primitive tissues.26 Similar mech-
anisms are observed in the transcriptional regulation of CCR5 as described in 
chapter 4.
Studying epigenetic processes in T cell differentiation has led to interesting in-
sights into disease pathogenesis of autoimmune diseases and of haematological 
malignancies. For instance, systemic lupus erythematosus (SLE) T-helper cells 
exhibit increased and prolonged expression of cell-surface CD154, spontaneously 
overproduce interleukin-10 (IL-10), but underproduce IFN-γ.27 In human SLE T cells, 
the HDAC inhibitor trichostatin A (TSA) reverses the skewed expression of CD154, 
IL-10 and IFN-γ products.27 This illustrates the potential use of Small Molecule 
Inhibitors (SMI) as a therapy for certain diseases (see page 138). T  cells from 
patients with SLE and RA were found to exhibit globally hypomethylated DNA.28 
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Widespread hypomethylation has been described in other disease contexts (e.g. 
T cell lymphomas or chronic lymphocytic leukemia cells), in which it is associat-
ed with gene activation and chromosomal instability.15,29 Interestingly, global DNA 
hypermethylation has been linked with a predisposition to, and natural history of 
atherosclerosis.2
Regulation at the single gene level
Although any change identified in the expression of epigenetic modifying en-
zymes is likely to be of importance in the pathogenesis of atherosclerosis, these 
enzymes are not solely responsible for cellular activity. Quite a few other molecules 
(e.g. chemokines and their receptors) are known to play a role in atherosclerosis.30 
To get a proper understanding on the transcriptional regulation of these genes, 
epigenetic regulation must be taken into account as well. In chapter 4, the regula-
tion of CCR5 was extensively studied, covering both classical regulation as well as 
epigenetic regulation.
In the initial characterization of the CCR5 promoter, it was suggested that CCR5 
transcription could be upregulated by NF-κB.31,32 Indeed, several potential binding 
sites for NF-κB have been found in the CCR5 P1-promoter.32,33 However, the results 
of the study by Kuipers et al. indicate that CCR5 expression is neither induced nor 
modulated by NF-κB.33 In addition, these authors also found binding sites for inter-
feron regulatory factors (IRFs) and CREB-1 in the CCR5 P1– and P2-promoters. Like 
for NF-kB and in contrast to CREB-1, Kuipers et al. could not establish a role for the 
IFNγ induced regulatory pathway in CCR5 transcription. By using various reporter 
assays, as well as by competition for CREB-1 binding-sites by inducible cAMP early 
repressor (ICER), which is induced by forskolin treatment, the authors concluded 
that CCR5 transcription is regulated by CREB-1.33 More recently, Banerjee et al. 
also showed that in the TF-1 human bone marrow progenitor cell line, CCR5 is reg-
ulated at the transcriptional level by the cAMP/PKA/CREB pathway.34
Transcriptional regulation of CCR5 cannot be explained by the sole action of 
transcription factors. Expression of CREB-1, however, is ubiquitous whereas CCR5 
transcription is not. The extensive study on epigenetic regulation of CCR5 in chap-
ter 4, showed the complex nature of epigenetic regulation and how this is used 
to fine-tune transcription levels. The work presented in chapter 4 illustrates that 
transcription, besides the activity of transcription factors, is the result of the sum 
of chromatin marks. This is exemplified by the chromatin state of CCR5 in mono-
cytes. Here, high levels of permissive and non-permissive histone modifications 
Summary & General discussion
135
are found together. Furthermore, the CCR5 promoter in monocytes is densely 
methylated at the DNA level. This results in intermediate CCR5 transcription levels 
in monocytes.
The epigenetic regulation of CCR5 transcription is determined by the interplay 
of DNA methylation and histone modifications. The mode of regulation is highly 
similar to the regulation of HLA‑G. HLA‑G, similar to CCR5, is transactivated by 
CREB-1. This cannot explain the tissue-restricted expression of HLA-G, which also 
suggests the involvement of epigenetic mechanisms in the regulation of HLA‑G 
transcription.35
Traditionally it was thought that chromatin was either marked by permissive or 
non-permissive marks (Figure 6–1, ‘classical’ regulation).36–38 The original histone 
code hypothesis, with an one-mark-to-one-module type of decoding, has received 
some criticism over the years (Ruthenburg et al.39 and references therein). Later 
work, however, showed that both permissive and non-permissive chromatin marks 
could coexist.40,41 Interestingly, activating and repressive modifications can even 
occur on the same nucleosome (Figure 6–1, ‘non-classical’ regulation).41
It has been proposed that a bivalent domain (characterized by the presence of 
H3K4Me3 and H3K27Me3) is merely an intermediate state.39 An idea strengthened 
by the finding that the ‘eraser’ of H3K9Me3 (considered as a repressive chroma-
tin mark) is recruited by binding H3K4Me3 (considered as a permissive chromatin 
mark).42,43 Additionally, removal of the H3K27Me3 (considered as a repressive chro-
matin mark) facilitates the recruitment of a H3K4 methyltransferase.44 However, in 
the context of cellular differentiation, co-localization of opposing epigenetic marks 
is also employed to poise genes for rapid activation or repression.40
Proximal modifications that constitute a putative ‘code’ need not be restricted 
to a single histone tail as originally anticipated,36 but may span two or more tails on 
a given nucleosome, adjacent nucleosomes, or nucleosomes that are discontinu-
ous in primary DNA sequence but spatially co-localized in a chromatin territory.45 
Furthermore, the multivalency of chromatin marks may also be thermodynami-
cally more favorable then monovalent histone marks.39 As reviewed by Rothbart 
and Strahl, multivalent chromatin marks may be far more common than originally 




The reduction in H3K27Me3 found in atherosclerotic plaques, as described in 
chapter 2 could be partially explained by the regulation seen at the CCR5 locus. In 
later stages, CCR5 expressing T cells are found in atherosclerotic plaques. It re-
mains to be established however, whether the reduction at a single locus would be 
enough to be detected by IHC. Furthermore, the reduction in H3K27Me3 as a result 
of T cell influx may be counterbalanced by the monocytes present, which show high 
levels of H3K27Me3.
In the context of atherosclerosis pathogenesis the demonstrated interference 
in epigenetic regulation is probably of more relevance. By adding inhibitors of epi-
genetic regulating enzymes, CCR5 transcription and CCR5 expression could be 
restored in non-CCR5 expressing cell-lines. This indicates that the epigenetic reg-
ulatory mechanism could form a potential target for pharmacological intervention. 








Figure 6–1.  Schematic representation of chromatin states encountered in the CCR5 locus. 
Chromatin can be marked by mainly repressive or mainly permissive marks, 
regarded as the classical euchromatin (green) and heterochromatin (red) states 
(“classical” regulation). Nowadays it is widely appreciated that more complex forms 
of chromatin exist, hallmarked by both repressive and permissive marks in the same 
locus (“non classical” regulation). Note: For clarity DNA-methylation is drawn on 
the internucleosomal-DNA, whereas it has been shown that methylated DNA co-
localizes also with nucleosomes.47 From: Wierda, R.J. et al. Biology (2012); 1, 869–79. 
doi:10.3390/biology1030869
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Altering CCR5 expression by use of these SMI could have a beneficiary effect on 
disease progression.
Genetics of epigenetics
Previously it was reported that transcription levels of the epigenetic regulatory 
enzyme PCAF (KAT2B) were significantly altered in a mouse model of reactive ste-
nosis. In addition it was found that the C-allele of a polymorphism 2481bp upstream 
of the transcription start-site of PCAF (rs2948080) is associated with a significant 
reduction in vascular morbidity and mortality. Given the location of the SNP it was 
investigated whether this SNP has an impact on the constitutive transcript lev-
els of PCAF in chapter 5. No significant differences were observed in constitutive 
PCAF transcript levels with regards to the genotype of either the monocytes or the 
HUVECs in the cohorts of investigated individuals.
The apparent lack of correlation between a promoter polymorphism and tran-
script levels has also been observed in other genetic systems of which the TNF 
promoter polymorphisms were elaborately studied.48 Similarly, the HLA-region 
has been known as a risk factor for Multiple Sclerosis for around 40 years.49 
Although the risk factor has been refined through the years to the DRB1*1501 allele, 
molecular mechanisms underlying the risk factor have not yet been completely 
elucidated.49 Astonishingly, GWA studies have identified hundreds of susceptibility 
genes for a large number of human conditions and quantitative traits.50 Deletion of 
the corresponding stretch of DNA in mice has shown that this part of the chromo-
some regulates cardiac expression of two genes approximately 100 kb away from 
the site of the variation.55 Yet in large human cohorts no association of the 9p21.3 
MI/CAD risk-variant with the expression of the two genes was found. Thus, “the 
mystery of the 9p21.3 locus remains wide open”.56 In the case of the PCAF -2481G/C 
polymorphism it may turn out that the identified SNP is influencing genomic regions 
located far away from the identified SNP, or even on different chromosomes. Even 
though it remains to be elucidated exactly how the PCAF -2481G/C polymorphism 
affects vascular morbidity and mortality, this SNP is illustrative of the complex in-
teractions between genetic and epigenetic regulation. When considering epigenetic 
modifying enzymes, such as PCAF, as pharmacological targets it is important to 
realize that also in epigenetic therapy pharmacogenomics is in play.
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Epigenetic regulation as a pharmacological target
SMI can influence the activity of epigenetic regulatory enzymes. Many of these 
compounds are relatively well tolerated as demonstrated in various clinical trials 
of these compounds in cancer therapy. As demonstrated in chapter 4 and in other 
studies,27 these SMIs can be used to influence gene expression. In atherosclerosis 
treatment, these inhibitors may be beneficial as well.
Epigenetic regulation is essential in keeping cells in their terminally differen-
tiated form. De-differentiation, or slowing down differentiation, can be beneficiary 
in atherosclerosis for instance by preventing foam cell formation. As described in 
chapter 3, KMTs play a role in the differentiation of monocytes into various line-
ages. Treatment with KMTi’s (such as DZNep and BIX-01294) could perhaps reduce 
the formation of foamcells in the vessel wall. Similarly, as shown in chapter 4, 
CCR5 can be modulated by SMI. By targeting CCR5 or other chemokine (receptors) 
the flux of immune cells to the vessel wall could potentially be modulated.
Although demonstrated in this thesis that the expression profile of a single gene 
could be altered by SMI, the potential use of SMI as curative agent requires careful 
consideration. Of high importance in this respect is the targeting of the SMI in order 
not to cause side effects elsewhere in the body. This is especially important given 
the fundamental gene regulation mechanism these inhibitors act upon. In principle 
these reactions can be avoided by targeted delivery and dosage. Careful selec-
tion of the SMI used based on its working mechanism can help to prevent these 
side effects as well. For instance Zebularine, a DNA methylation inhibitor, requires 
incorporation into the DNA and therefore may affect dividing cells stronger than 
non-dividing cells.
Thorough understanding of interactions within the cell is also necessary to 
predict potential side effects in SMI-therapy. Epigenetic regulation is part of a 
complex network of interactions. Most, if not all genes, are under epigenetic con-
trol. Intervention in this mechanism may result in unwanted deregulation of certain 
genes. This can be caused either as a result of direct intervention in transcription 
or as a result of disruption of long-range interactions within the nucleus.
Recommendations for future research
Determining the onset of complex multifactorial diseases such as atheroscle-
rosis might be best investigated in a multi-disciplinary approach. Starting at a 
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demographic or epidemiological approach and then cascading down to individual 
molecular pathways. From an epidemiological point of view quite some knowledge 
has been gained on atherosclerosis in the past years. Many potential risk factors 
have been found, and many GWA studies have found potentially interesting genomic 
targets. However, these findings are often hard to translate to molecular underpin-
nings as has been demonstrated in chapter 5.
On the other hand, in vitro studies or even mouse studies are often hard to trans-
late to clinical settings. Much can therefore be gained by focusing research on 
clinically relevant materials, e.g. tissue and biological fluids present in various bio 
banks. In a similar approach as in chapter 2, it would be possible to identify po-
tential targets for epigenetic regulation by using ChIP-Seq strategies on plaque 
material. The results of such studies could provide fuel for further in vitro studies.
Complicating such an approach however is the lack of availability of such ma-
terial. Materials acquired are almost always post-mortem, which may influence 
the results obtained. As a result research is often performed on more easily avail-
able materials or models such as peripheral blood, or in vitro and mouse models. 
Replicating plaque formation could advance the field much in this respect. Similar 
attempts have been undertaken in creating in vitro skin, but is must be noted that 
plaque material is much more complicated in composition then the epidermis. In 
case successful plaque models can be created in vitro, these could be used to test 
the molecular mechanisms underlying plaque development.
Furthermore, a better understanding of the mechanisms underlying differenti-
ation of monocytes, such as presented in chapter 3, and other cell types may help 
us in understanding the pathology of plaque formation. A better understanding of 
these fundamental processes may also be of benefit in the understanding of other 
diseases with an inflammatory component, such as MS and diabetes. Genome-
wide epigenetic profiling may lead to new insights on loci involved in differentiation. 
As illustrated by the work in chapter 4 it is important to investigate the broadest 
repertoire of epigenetic marks possible. Such genome-wide studies should be ac-
companied with more detailed mechanistic studies. Just as is the case with GWA 
studies, genome-wide epigenetic profiling may provide us with data that is hard to 




The work presented in this thesis provides a strong indication that H3K27Me3 
levels are lowered in more advanced plaques. This is not accompanied by any 
change in enzymes involved in establishing or making the H3K27Me3 mark into 
effect. These observations, however, require further validation by other methods. 
Furthermore it was shown that KMTs are involved in the differentiation of mono-
cytes into DCs and that this process might be potentially steered by using SMI.
In addition, the complexity of epigenetic regulation is demonstrated at the CCR5 
locus. The regulation of CCR5 shows that transcription levels are the result of the 
sum of epigenetic modifications in addition to classical gene regulation by tran-
scription factors. The interplay between classical genetic regulation and epigenetic 
regulation is underlined by the SNP (rs2948080) found in the PCAF gene. Although 
this SNP does not have a direct influence on PCAF transcription, the SNP itself is 
associated with higher vascular mortality. Potentially this is the result of higher-or-
der or long-range genomic interactions. Finally, the work presented on monocyte 
differentiation and CCR5 regulation shows the potential of ‘epigenetic therapy’ by 
using SMI.
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Hart- en vaatziekten zijn momenteel doodsoorzaak nummer één in ontwikkel-
de westerse landen. De primaire oorzaak van coronair vaatlijden en hartinfarct is 
atherosclerose. In de volksmond, onterecht, wellicht beter bekend als aderverkal-
king. De klinische manifestatie van atherosclerose is het ontstaan van zogenaamde 
plaques in de vaatwand. Het ontstaan van deze plaques wordt waarschijnlijk ver-
oorzaakt door geoxideerd LDL cholesterol (OxLDL). Onder invloed van deze stof 
migreren een bepaald type cellen (monocyten) uit het bloed de vaatwand in. Daar 
differentiëren deze cellen in macrofagen, die proberen de OxLDL op te ruimen. 
Macrofagen kunnen OxLDL echter niet verteren, maar blijven deze stof wel continu 
opnemen. Hierdoor ontstaan opgezwollen macrofagen, vol met OxLDL; de zoge-
naamde schuimcellen. De aanwezigheid van deze schuimcellen is wat de plaques 
vormt in de vaatwand. Monocyten en macrofagen zijn onderdeel van ons immuun-
systeem. De voortdurende activatie van het immuunsysteem door OxLDL zorgt 
voor een chronische ontsteking in de vaatwand. De vaatwand zal onder druk van 
de groter wordende plaque initieel verwijden, maar uiteindelijk vernauwd de vaat-
wand zich. Als een vat te sterk vernauwd is, of door het scheuren van een plaque 
verstopt, stopt de bloedsomloop hetgeen een infarct veroorzaakt.
Het ontstaan van atherosclerose wordt gekenmerkt door vele omgevingsfac-
toren, zoals voeding en roken. Daarom wordt gedacht dat epigenetische regulatie 
een belangrijke rol speelt in het ontstaan van plaques, de klinische manifestatie 
van atherosclerose. Epigenetische regulatie is een proces dat cellen gebruiken om 
genexpressie te reguleren. In tegenstelling tot vele andere manieren van regulatie 
is epigenetische regulatie stabiel en blijft het behouden door celdivisies heen, maar 
zelfs door generaties heen kunnen epigenetische kenmerken bewaard blijven. 
Epigenetische regulatie bestaat uit het aanbrengen van chemische modificaties 
(methylgroepen) op het DNA, zonder dat daarbij de DNA-sequentie veranderd 
wordt. Daarnaast worden de eiwitten waaromheen het DNA opgewonden zit (his-
tonen) voorzien van chemische modificaties. Of een gen tot expressie komt of niet 
wordt bepaald door de (combinatie van) modificaties die zijn aangebracht. In dit 
proefschrift wordt gekeken naar de invloed van epigenetische genregulatie op het 
ontstaan van atherosclerose.
Hoofdstuk 2 van dit proefschrift beschrijft het onderzoek naar de aanwezigheid 
van epigenetische modificaties in plaque-materiaal. Dit materiaal is verkregen van 
orgaandonoren en vervolgens in dunne (4µm dik) plakjes gesneden. Door middel 
van immunohistochemie is het mogelijk de chemische modificaties van histonen, 
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die de basis vormen van epigenetische regulatie, aan te kleuren. Door middel van 
de computertechniek beschreven in hoofdstuk 2 werden het aantal cellen met en 
zonder epigenetische kenmerken geteld. Daarna is een correlatie gemaakt tussen 
het plaque stadium (1 = vroeg tot 6 = laat stadium). Er werd een zwakke, maar signi-
ficante correlatie gevonden in één van de epigenetische markers (H3K27Me3). De 
eiwitten die deze modificatie lezen, aanbrengen of verwijderen laten echter geen 
veranderingen in expressie zien. Hierbij moet echter aangemerkt worden dat deze 
resultaten mogelijk vertekend zijn door de gebruikte technieken en de gevoeligheid 
daarvan.
In hoofdstuk 3 wordt de differentiatie van monocyten in andere celtypen op 
moleculair niveau beschreven. Monocyten, geïsoleerd uit het bloed van gezonde 
vrijwilligers, worden in vitro gedifferentieerd tot dendritische cellen en macrofagen 
(type 1 en type 2). Door middel van kwantitatieve PCR is in deze cellen gekeken 
naar de RNA transcriptieniveaus van 59 genen betrokken bij epigenetische regula-
tie. Het blijkt dat van de vier verschillende klassen van enzymen er drie verschillen 
in transcriptie tussen monocyten en gedifferentieerde monocyten: KMTs, KDMs 
en HDACs. Van alle bekeken genen is er alleen bij KMT1C sprake van significant 
verschillende transcriptie. Wanneer tijdens de differentiatie van monocyten naar 
dendritische cellen (DCs) dit enzym geblokkeerd wordt door BIX-01294, wordt 
de transcriptie van DC‑SIGN (typerend voor DCs) verlaagd. Op eiwitniveau heeft 
BIX-01294 geen effect op DC‑SIGN transcriptie. Echter wanneer KMT-activiteit in 
het algemeen geremd wordt door DZNep is er ook minder DC-SIGN aanwezig op 
het celoppervlak. Dit effect wordt versterkt wanneer DZNep en BIX-01294 gecom-
bineerd worden. Dit toont aan dat KMT1c een rol speelt bij de differentiatie van 
monocyten naar DCs.
In hoofdstuk 4 wordt in detail beschreven hoe epigenetische regulatie de ex-
pressie van een gen beïnvloed. Het CCR5 gen, wat betrokken is bij het ontstaan 
van atherosclerose komt in verschillende niveaus tot expressie in verschillende 
celtypen. Klassieke genregulatie, door middel van transcriptiefactoren die binden 
op het DNA kan deze verschillen niet verklaren. CCR5 wordt slechts door de tran-
scriptiefactor CREB-1 gereguleerd, maar deze transcriptie factor is vrijwel continu 
aanwezig in alle cellen. Het verschil kan wel verklaard worden door de ‘epigeneti-
sche status’ van het CCR5 gen. In cellen waar CCR5 niet tot expressie komt zit het 
gen ook epigenetisch ‘op slot’, waarbij in cellen die CCR5 tot expressie brengen de 
epigenetische status daartoe ook gunstig is. Dit is compleet in lijn met de huidige 
theorie over epigenetische regulatie. Wat echter opvalt, is dat de epigenetica hier 
ook de mate van transcriptie bepaald, iets wat tot nu toe maar in een paar gevallen 
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beschreven is. Belangrijk bij het bestuderen van epigenetische regulatie is dus om 
alle factoren zowel, positief als negatief regulerend, in ogenschouw te nemen.
In hoofdstuk 5 wordt een zogenaamd polymorfisme in de promotor van een 
epigenetisch gen beschreven: PCAF. In een eerdere studie werd dit polymorfisme 
gecorreleerd met een grotere vatbaarheid voor atherosclerose. In diezelfde studie 
werd eveneens aangetoond dat op de plek van het polymorfisme eiwitten kunnen 
binden en dat deze binding afhankelijk is van de aanwezige base in het DNA. In het 
onderzoek beschreven in dit hoofdstuk is vervolgens gekeken of deze eiwitbinding 
ook leidt tot een verschil in expressie. Deze expressie is gecontroleerd in cellen die 
aanwezig zijn in de vaatwand (HUVECs) en in de eerder beschreven monocyten. Er 
kon geen verschil aangetoond worden in expressie tussen de verschillende geno-
typen van het polymorfisme. Het verschil in vatbaarheid voor atherosclerose moet 
dus op een andere manier verklaard worden dan door een verschil in expressie van 
het PCAF gen.
Tot slot worden de gevonden resultaten in hoofdstuk 6 samengevat en bedis-
cussieerd. Aan het einde van dit hoofdstuk worden aanbevelingen gedaan voor 
toekomstig onderzoek. Met name wordt aanbovelen om meer epigenetisch ge-
reguleerde loci te vinden middel van CHiP-Sequencing en de uitkomsten hiervan 
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te Velsen). In 2001 behaalde hij zijn VWO diploma aan het Kennemer Lyceum te 
Overveen. In datzelfde jaar begon hij aan zijn opleiding Life Science & Technology 
aan de TU Delft en de Universiteit Leiden. Wetenschappelijke ervaring werd opge-
daan tijdens een tweetal stages. De eerste onder leiding van prof. dr. R.C. Hoeben, 
bij de vakgroep virologie aan de afdeling Moleculaire Celbiologie van het Leids 
Universitair Medisch centrum waar onderzoek werd gedaan naar de gly-ala repeat 
van het Epstein-Barr virus. Daarna werd een stage voltooid op de afdeling virologie 
op het ErasmusMC in Rotterdam onder leiding van prof. dr. R.A.M. Fouchier en 
afdelingshoofd prof. dr. A.D.M.E. Osterhaus. Tijdens deze laatste stage bestudeer-
de hij het fusie-eiwit van het humane metapneumovirus in een poging een vaccin 
te ontwikkelen tegen dit virus. In december 2007 behaalde hij zijn masterdiplo-
ma. In 2008 werd begonnen aan het promotieonderzoek waarvan de resultaten 
zijn beschreven in dit proefschrift. Het onderzoek beschreven in dit proefschrift is 
uitgevoerd bij de sectie moleculaire biologie van de afdeling Immunohematologie 
en Bloedtransfusie van het LUMC onder leiding van prof. dr. P.J. van den Elsen. 
Sinds juni 2012 is Rutger werkzaam als Field Application Scientist bij Thermo 
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Dit dankwoord is misschien het enige hoodstuk in dit proefschrift dat werkelijk 
door iedereen gelezen wordt. Het is een cliché, maar daarom nog niet minder waar: 
dit proefschrift was er niet geweest zonder de hulp van velen. Op mij rust nu dan 
ook de schone taak deze mensen te bedanken. De dank die ik wil uitspreken is gro-
ter dan zich laat vatten in de beperkte woorden van dit dankwoord.
In de eerste plaats wil ik graag mijn promotor bedanken. Peter, bedankt voor 
het mij leren schrijven van een wetenschappelijk paper en het hoe de resultaten 
te moeten ‘verkopen aan de buitenwereld’. Dit proefschrift is het resultaat van dat 
leerproces, maar ook van het stimuleren van een goede werkomgeving met ac-
tiviteiten buiten het LUMC. Marja, bedankt voor alle tijd die je gespendeerd hebt 
aan primers testen en western-blotten (helaas niet altijd even succesvol) voor dit 
proefschrift. Jouw rijke ervaring met verschillende technieken, maar ook van het 
LUMC, heeft mij ontzettend veel geholpen. Miss-monocyt – Sacha – het was goed 
om iemand naast me te hebben met een kritische blik op het onderzoek en de 
zaken er omheen. Ook jouw kennis over de monocyt is een grote bijdrage geweest 
voor dit proefschrift, hoewel ik me stellig afvraag of we werkelijk kunnen spreken 
over dé monocyt.
De vele studenten die hun stage hebben gewijd aan dit onderzoek verdienen 
uiteraard ook een plek in dit dankwoord. Jurgen, Inge, Alice, Marieke Goedhart, 
Marieke Hogervorst, Xanne bedankt; Sylvia & Lucia grazie!
Niet iedereen die een belangrijke bijdrage heeft geleverd heeft een pipet vast-
gehouden (of in ieder geval niet gepipetteerd tot een resultaat in dit onderzoek). 
Toch hebben zij niet een mindere bijdrage geleverd aan het tot stand komen van 
dit boekje. Leden van de FECO: Arno, Jacky, Anouk, Niels, Joost, Josefine & Anna-
Sophia dank jullie wel voor alle mooie borrels die we samen georganiseerd hebben. 
Angela, bedankt voor de keren dat je wilde luisteren naar mijn promotie-perikelen. 
Rike, Ihre Fröhlichkeit war motivierend. Viel Glück mit Ihrem post-doc in den USA! 
Monique, bedankt voor je gezelligheid en voor het posten van al die mooie foto’s op 
je blog. Marie-Louise het is alweer een aantal jaar geleden dat je aan mij schreef: 
“Rutger, dat boekje komt wel”. Ik had er toen eerlijk gezegd een hard hoofd in, maar 
je had gelijk; het is gelukt.
Addenda
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De ‘professoren in de roeitechniek’: Bart, Rudi, Rudy, Michel, Jack en Marien, 
bedankt dat ik bij jullie (of dankzij jullie) even stoom kon afblazen. Ik heb vaak ver-
stek laten gaan met promoveren als excuus; dat is nu verleden tijd.
Natuurlijk wil ik ook mijn paranimfen bedanken. Bas & Martijn hartelijk dank 
voor jullie steun naar aanloop van (en tijdens) de verdediging. Hartelijk dank ook 
voor de inspiratie voor het bedenken van de stellingen. Martijn, alles wat ook maar 
een beetje lijkt op wetenschap wordt door jou altijd kritisich benaderd. Dat is een 
waardevolle eigenschap voor een wetenschapper en arts en heeft mij ook zeker 
geholpen. De manier waarop je de exchange students uit Geneve wist te bewegen 
zal altijd tot de verbeelding blijven spreken. Bas, de avonden waarop wij met veel 
enthousiasme het metabolisme van S. Cerevisiae hebben bestudeerd zijn van on-
schatbare waarde geweest voor het tot stand komen van dit proefschrift. Ik hoop 
dat we daar nog lang mee door kunnen gaan.
Wat ik allemaal uitvoerde op het LUMC is jullie volgens mij nooit helemaal dui-
delijk geweest. Ook de resultaten die hier beschreven staan zullen vast bij jullie 
duizelen. Maar zonder jullie steun, pap en mam, was mijn studie nooit gelukt en 
was dit boekje er nooit geweest. Bedankt!
De laatste regels, je zei het zelf al eens, die zijn voor een speciaal iemand. Lieve 
Tessa, bedankt! Bedankt voor al die keren dat je mij weer achter de computer hebt 










APC Antigen Presenting Cell
ATCC American Type Culture Collection
BMI1 B Lymphoma Mo-MLV Insertion Region 
1 Homolog
CAD Coronary Artery Disease
cAMP Cyclic Adenosime Mono Phosphate
CCR5 CC-Motif Chemokine Receptor 5
ChIP Chromatin Immunoprecipitation
CIITA Class II Transactivator
COX-2 Cyclooxygenase-2
CREB Camp-Responsive Element Binding 
Protein








EMSA Electrophoretic Mobility Shift Assay
ER Oestrogen Receptor
EZH2 Enhancer of Zeste Homolog 2




HDL High Density Lipoprotein
HS Human Serum
HUVEC Human Umbilical Vein Endothelial Cell




IRF Interferon Regulatory Factor




LDL Low Density Lipoprotein
LSD1 Lysine-Specific Histone Demethylase 1
M-CSF macrophage colony- stimulating factor
MHC Major Histocompatibility Complex
Mφ Macrophage
NF-κB Nuclear Factor Kappa-Light-Chain-
Enhancer of Activated B Cells
NK Cell Natural Killer Cell
NKT Cell Natural Killer T Cell
NOS Nitric Oxide Synthetase
OxLDL Oxidized Low-Density Lipoprotein
PBMC Peripheral Blood Mononuclear Cell
PBS Phosphate Buffered Saline
PcG Polycomb Group
PCI Percutaneous Coronary Intervention
PRC Polycomb Repressive Complex
qPCR Quantitative Polymerase Chain 
Reaction
SAHA Suberoylanilide Hydroxamic Acid
siRNA Small Interfering RNA
SIRT Sirtuin
SLE Systemic Lupus Erythematosus
SMC Smooth Muscle Cells
SMI Small Molecule Inhibitor
SNP Single Nucleotide Polymorphism
TF Tissue Factor
TGF-β Transforming Growth Factor Beta
TNF-α Tumour Necrosis Factor Αlpha
TSA Trichostatin A
VALT Vasculature-Associated Lymphoid 
Tissue
vEC Vascular Endothelial Cells
VPA Valproic Acid
vSMC Vascular Smooth Muscle Cell

